

BA

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60991 A2(51) International Patent Classification⁷: C12N 9/12,
15/54, 5/10, A01K 67/027, C07K 16/40, C12Q 1/68,
C12N 15/11, A61K 38/45, G01N 33/53

(21) International Application Number: PCT/US01/05240

(22) International Filing Date: 16 February 2001 (16.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/183,682	17 February 2000 (17.02.2000)	US
60/186,559	2 March 2000 (02.03.2000)	US
60/188,606	9 March 2000 (09.03.2000)	US
60/189,998	17 March 2000 (17.03.2000)	US
60/193,851	30 March 2000 (30.03.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/183,682 (CIP)
Filed on	17 February 2000 (17.02.2000)
US	60/186,559 (CIP)
Filed on	2 March 2000 (02.03.2000)
US	60/188,606 (CIP)
Filed on	9 March 2000 (09.03.2000)
US	60/189,998 (CIP)
Filed on	17 March 2000 (17.03.2000)
US	60/193,851 (CIP)
Filed on	30 March 2000 (30.03.2000)

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BUFORD, Neil [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US). GANDHI, Ameena, R. [US/US]; 837 Roble Avenue #1, Menlo Park, CA 94025 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94024 (US). KHAN, Farrah, A. [IN/US]; 333 Escuela Avenue #221, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HAFALIA, April [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). SHIH, Leo, L.

[US/US]; Apartment B, 1081 Tanland Drive, Palo Alto, CA 94303 (US). TRIBOULEY, Catherine, M. [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). YAO, Monique, G. [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). BURRILL, John, D. [US/US]; 650 Emerald Hill Road, Redwood City, CA 94061 (US). MARCUS, Gregory, A. [US/US]; 1713 Connecticut Drive, Redwood City, CA 94061 (US). ZINGLER, Kurt, A. [US/US]; 723 Ashbury Street #C, San Francisco, CA 94117 (US). LU, Dyung, Aina, M. [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). POLICKY, Jennifer, L. [US/US]; 4864 National Avenue, San Jose, CA 95124 (US). GRIFFIN, Jennifer, A. [US/US]; 181 Irene Court #11, Belmont, CA 94002 (US). THORNTON, Michael [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). NGUYEN, Dannel, B. [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). WALSH, Roderick, T. [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

BEST AVAILABLE COPY



WO 01/60991 A2



HUMAN KINASES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human kinases and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, atherosclerosis and other cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

BACKGROUND OF THE INVENTION

Kinases comprise the largest known enzyme superfamily and vary widely in their target molecules. Kinases catalyze the transfer of high energy phosphate groups from a phosphate donor to a phosphate acceptor. Nucleotides usually serve as the phosphate donor in these reactions, with most kinases utilizing adenosine triphosphate (ATP). The phosphate acceptor can be any of a variety of molecules, including nucleosides, nucleotides, lipids, carbohydrates, and proteins. Proteins are phosphorylated on hydroxyamino acids. Addition of a phosphate group alters the local charge on the acceptor molecule, causing internal conformational changes and potentially influencing intermolecular contacts. Reversible protein phosphorylation is the primary method for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors. The activated proteins initiate the cell's intracellular response by way of intracellular signaling pathways and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

Kinases are involved in all aspects of a cell's function, from basic metabolic processes, such as glycolysis, to cell-cycle regulation, differentiation, and communication with the extracellular environment through signal transduction cascades. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

There are two classes of protein kinases. One class, protein tyrosine kinases (PTKs), phosphorylates tyrosine residues, and the other class, protein serine/threonine kinases (STKs), phosphorylates serine and threonine residues. Some PTKs and STKs possess structural characteristics of both families and have dual specificity for both tyrosine and serine/threonine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family. The protein kinase catalytic

domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a tyrosine, serine, or threonine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. PTKs and STKs also contain distinct sequence motifs in subdomains VI and VIII which may confer hydroxyamino acid specificity.

In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Book, Vol I, pp. 17-20 Academic Press, San Diego CA.). In particular, two protein kinase signature sequences have been identified in the kinase domain, the first containing an active site lysine residue involved in ATP binding, and the second containing an aspartate residue important for catalytic activity. If a protein analyzed includes the two protein kinase signatures, the probability of that protein being a protein kinase is close to 100%. (PROSITE: PDOC00100, November 1995).

Protein Tyrosine Kinases

Protein tyrosine kinases (PTKs) may be classified as either transmembrane, receptor PTKs or nontransmembrane, nonreceptor PTK proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Growth factors bind to the receptor tyrosine kinase (RTK), which causes the receptor to phosphorylate itself (autophosphorylation) and specific intracellular second messenger proteins. Growth factors (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Nontransmembrane, nonreceptor PTKs lack transmembrane regions and, instead, form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin), and antigen-specific receptors on T and B lymphocytes.

Many PTKs were first identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and N.K. Tonks (1992) *Annu. Rev. Cell Biol.* 8:463-493). Regulation of PTK activity may therefore be an important strategy in

controlling some types of cancer.

Protein Serine/Threonine Kinases

Protein serine/threonine kinases (STKs) are nontransmembrane proteins. A subclass of STKs are known as ERKs (extracellular signal regulated kinases) or MAPs (mitogen-activated protein
5 kinases) and are activated after cell stimulation by a variety of hormones and growth factors. Cell stimulation induces a signaling cascade leading to phosphorylation of MEK (MAP/ERK kinase) which, in turn, activates ERK via serine and threonine phosphorylation. A varied number of proteins represent the downstream effectors for the active ERK and implicate it in the control of cell proliferation and differentiation, as well as regulation of the cytoskeleton. Activation of ERK is
10 normally transient, and cells possess dual specificity phosphatases that are responsible for its down-regulation. Also, numerous studies have shown that elevated ERK activity is associated with some cancers. Other STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), calcium-calmodulin (CaM) dependent protein kinases, and the mitogen-activated protein kinases (MAP); the cyclin-dependent protein kinases; checkpoint
15 and cell cycle kinases; proliferation-related kinases; 5'-AMP-activated protein kinases; and kinases involved in apoptosis.

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic ADP ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The
20 PKAs are involved in mediating hormone-induced cellular responses and are activated by cAMP produced within the cell in response to hormone stimulation. cAMP is an intracellular mediator of hormone action in all animal cells that have been studied. Hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in
25 all animal cells and is thought to account for the effects of cAMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY, pp. 416-431, 1887).

The casein kinase I (CKI) gene family is another subfamily of serine/threonine protein
30 kinases. This continuously expanding group of kinases have been implicated in the regulation of numerous cytoplasmic and nuclear processes, including cell metabolism, and DNA replication and repair. CKI enzymes are present in the membranes, nucleus, cytoplasm and cytoskeleton of eukaryotic cells, and on the mitotic spindles of mammalian cells (Fish, K.J. et al. (1995) J. Biol. Chem. 270:14875-14883).

35 The CKI family members all have a short amino-terminal domain of 9-76 amino acids, a

highly conserved kinase domain of 284 amino acids, and a variable carboxyl-terminal domain that ranges from 24 to over 200 amino acids in length (Cegielska, A. et al. (1998) J. Biol. Chem. 273:1357-1364). The CKI family is comprised of highly related proteins, as seen by the identification of isoforms of casein kinase I from a variety of sources. There are at least five mammalian isoforms, α , β , γ , δ , and ϵ . Fish et al., identified CKI-epsilon from a human placenta cDNA library. It is a basic protein of 416 amino acids and is closest to CKI-delta. Through recombinant expression, it was determined to phosphorylate known CKI substrates and was inhibited by the CKI-specific inhibitor CKI-7. The human gene for CKI-epsilon was able to rescue yeast with a slow-growth phenotype caused by deletion of the yeast CKI locus, HRR250 (Fish et al., supra).

- 10 The mammalian circadian mutation tau was found to be a semidominant autosomal allele of CKI-epsilon that markedly shortens period length of circadian rhythms in Syrian hamsters. The tau locus is encoded by casein kinase I-epsilon, which is also a homolog of the Drosophila circadian gene double-time. Studies of both the wildtype and tau mutant CKI-epsilon enzyme indicated that the mutant enzyme has a noticeable reduction in the maximum velocity and autophosphorylation state.
- 15 Further, *in vitro*, CKI-epsilon is able to interact with mammalian PERIOD proteins, while the mutant enzyme is deficient in its ability to phosphorylate PERIOD. Lowrey et al., have proposed that CKI-epsilon plays a major role in delaying the negative feedback signal within the transcription-translation-based autoregulatory loop that composes the core of the circadian mechanism. Therefore the CKI-epsilon enzyme is an ideal target for pharmaceutical compounds influencing circadian
- 20 rhythms, jet-lag and sleep, in addition to other physiologic and metabolic processes under circadian regulation (Lowrey, P.L. et al. (2000) Science 288:483-491).

Calcium-Calmodulin Dependent Protein Kinases

- Calcium-calmodulin dependent (CaM) kinases are involved in regulation of smooth muscle contraction, glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and
- 25 CaM kinase II). CaM dependent protein kinases are activated by calmodulin, an intracellular calcium receptor, in response to the concentration of free calcium in the cell. Many CaM kinases are also activated by phosphorylation. Some CaM kinases are also activated by autophosphorylation or by other regulatory kinases. CaM kinase I phosphorylates a variety of substrates including the neurotransmitter-related proteins synapsin I and II, the gene transcription regulator, CREB, and the
- 30 cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et.al. (1995) EMBO J. 14:3679-3686). CaM kinase II also phosphorylates synapsin at different sites and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. CaM kinase II controls the synthesis of catecholamines and serotonin, through phosphorylation/activation of tyrosine hydroxylase and tryptophan hydroxylase, respectively (Fujisawa, H. (1990) BioEssays
- 35 12:27-29). The mRNA encoding a calmodulin-binding protein kinase-like protein was found to be

enriched in mammalian forebrain. This protein is associated with vesicles in both axons and dendrites and accumulates largely postnatally. The amino acid sequence of this protein is similar to CaM-dependent STKs, and the protein binds calmodulin in the presence of calcium (Godbout, M. et al. (1994) J. Neurosci. 14:1-13).

5 Mitogen-Activated Protein Kinases

The mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades are another STK family that regulates intracellular signaling pathways. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S.E. and R.A. Weinberg (1993) Nature 365:781-783). MAP kinase signaling pathways are present in mammalian cells as well as in yeast. The extracellular stimuli which activate MAP kinase pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

15 Cyclin-Dependent Protein Kinases

The cyclin-dependent protein kinases (CDKs) are STKs that control the progression of cells through the cell cycle. The entry and exit of a cell from mitosis are regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins are small regulatory proteins that bind to and activate CDKs, which then phosphorylate and activate selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to cyclin binding, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue on the CDK.

Another family of STKs associated with the cell cycle are the NIMA (never in mitosis)-related kinases (Neks). Both CDKs and Neks are involved in duplication, maturation, and separation of the microtubule organizing center, the centrosome, in animal cells (Fry, A.M. et al. (1998) EMBO J. 17:470-481).

25 Checkpoint and Cell Cycle Kinases

In the process of cell division, the order and timing of cell cycle transitions are under control of cell cycle checkpoints, which ensure that critical events such as DNA replication and chromosome segregation are carried out with precision. If DNA is damaged, e.g. by radiation, a checkpoint pathway is activated that arrests the cell cycle to provide time for repair. If the damage is extensive, apoptosis is induced. In the absence of such checkpoints, the damaged DNA is inherited by aberrant cells which may cause proliferative disorders such as cancer. Protein kinases play an important role in this process. For example, a specific kinase, checkpoint kinase 1 (Chk1), has been identified in

yeast and mammals, and is activated by DNA damage in yeast. Activation of Chk1 leads to the arrest of the cell at the G2/M transition (Sanchez, Y. et al. (1997) Science 277:1497-1501). Specifically, Chk1 phosphorylates the cell division cycle phosphatase CDC25, inhibiting its normal function which is to dephosphorylate and activate the cyclin-dependent kinase Cdc2. Cdc2 activation controls the entry of cells into mitosis (Peng, C.-Y. et al. (1997) Science 277:1501-1505). Thus, activation of Chk1 prevents the damaged cell from entering mitosis. A similar deficiency in a checkpoint kinase, such as Chk1, may also contribute to cancer by failure to arrest cells with damaged DNA at other checkpoints such as G2/M.

Proliferation-Related Kinases

Proliferation-related kinase is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryocytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-19408). Proliferation-related kinase is related to the polo (derived from *Drosophila* polo gene) family of STKs implicated in cell division. Proliferation-related kinase is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation.

5'-AMP-activated protein kinase

A ligand-activated STK protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) J. Biol. Chem. 271:8675-8681). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

Kinases in Apoptosis

Apoptosis is a highly regulated signaling pathway leading to cell death that plays a crucial role in tissue development and homeostasis. Deregulation of this process is associated with the pathogenesis of a number of diseases including autoimmune disease, neurodegenerative disorders, and cancer. Various STKs play key roles in this process. ZIP kinase is an STK containing a C-terminal leucine zipper domain in addition to its N-terminal protein kinase domain. This C-terminal domain appears to mediate homodimerization and activation of the kinase as well as interactions with transcription factors such as activating transcription factor, ATF4, a member of the cyclic-AMP responsive element binding protein (ATF/CREB) family of transcriptional factors (Sanjo, H. et al. (1998) J. Biol. Chem. 273:29066-29071). DRAK1 and DRAK2 are STKs that share

homology with the death-associated protein kinases (DAP kinases), known to function in interferon- γ induced apoptosis (Sanjo et al., supra). Like ZIP kinase, DAP kinases contain a C-terminal protein-protein interaction domain, in the form of ankyrin repeats, in addition to the N-terminal kinase domain. ZIP, DAP, and DRAK kinases induce morphological changes associated with apoptosis when transfected into NIH3T3 cells (Sanjo et al., supra). However, deletion of either the N-terminal kinase catalytic domain or the C-terminal domain of these proteins abolishes apoptosis activity, indicating that in addition to the kinase activity, activity in the C-terminal domain is also necessary for apoptosis, possibly as an interacting domain with a regulator or a specific substrate.

RICK is another STK recently identified as mediating a specific apoptotic pathway involving the death receptor, CD95 (Inohara, N. et al. (1998) J. Biol. Chem. 273:12296-12300). CD95 is a member of the tumor necrosis factor receptor superfamily and plays a critical role in the regulation and homeostasis of the immune system (Nagata, S. (1997) Cell 88:355-365). The CD95 receptor signaling pathway involves recruitment of various intracellular molecules to a receptor complex following ligand binding. This process includes recruitment of the cysteine protease caspase-8 which, in turn, activates a caspase cascade leading to cell death. RICK is composed of an N-terminal kinase catalytic domain and a C-terminal "caspase-recruitment" domain that interacts with caspase-like domains, indicating that RICK plays a role in the recruitment of caspase-8. This interpretation is supported by the fact that the expression of RICK in human 293T cells promotes activation of caspase-8 and potentiates the induction of apoptosis by various proteins involved in the CD95 apoptosis pathway (Inohara et al., supra).

Mitochondrial Protein Kinases

A novel class of eukaryotic kinases, related by sequence to prokaryotic histidine protein kinases, are the mitochondrial protein kinases (MPKs) which seem to have no sequence similarity with other eukaryotic protein kinases. These protein kinases are located exclusively in the mitochondrial matrix space and may have evolved from genes originally present in respiration-dependent bacteria which were endocytosed by primitive eukaryotic cells. MPKs are responsible for phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase complexes (Harris, R.A. et al. (1995) Adv. Enzyme Regul. 34:147-162). Five MPKs have been identified. Four members correspond to pyruvate dehydrogenase kinase isozymes, regulating the activity of the pyruvate dehydrogenase complex, which is an important regulatory enzyme at the interface between glycolysis and the citric acid cycle. The fifth member corresponds to a branched-chain alpha-ketoacid dehydrogenase kinase, important in the regulation of the pathway for the disposal of branched-chain amino acids. (Harris, R.A. et al. (1997) Adv. Enzyme Regul. 37:271-293). Both starvation and the diabetic state are known to result in a great increase in the activity of the pyruvate dehydrogenase kinase in the liver, heart and muscle of the rat. This increase contributes

in both disease states to the phosphorylation and inactivation of the pyruvate dehydrogenase complex and conservation of pyruvate and lactate for gluconeogenesis (Harris (1995) supra).

KINASES WITH NON-PROTEIN SUBSTRATES

5

Lipid and Inositol kinases

Lipid kinases phosphorylate hydroxyl residues on lipid head groups. A family of kinases involved in phosphorylation of phosphatidylinositol (PI) has been described, each member phosphorylating a specific carbon on the inositol ring (Leevers, S.J. et al. (1999) Curr. Opin. Cell. Biol. 11:219-225). The phosphorylation of phosphatidylinositol is involved in activation of the protein kinase C signaling pathway. The inositol phospholipids (phosphoinositides) intracellular signaling pathway begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane by inositol kinases, thus converting PI residues to the biphosphate state (PIP₂). PIP₂ is then cleaved into inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling pathways. Cellular responses that are mediated by these pathways are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

PI 3-kinase (PI3K), which phosphorylates the D3 position of PI and its derivatives, has a central role in growth factor signal cascades involved in cell growth, differentiation, and metabolism. PI3K is a heterodimer consisting of an adapter subunit and a catalytic subunit. The adapter subunit acts as a scaffolding protein, interacting with specific tyrosine-phosphorylated proteins, lipid moieties, and other cytosolic factors. When the adapter subunit binds tyrosine phosphorylated targets, such as the insulin responsive substrate (IRS)-1, the catalytic subunit is activated and converts PI (4,5) biphosphate (PIP₂) to PI (3,4,5) P₃ (PIP₃). PIP₃ then activates a number of other proteins, including PKA, protein kinase B (PKB), protein kinase C (PKC), glycogen synthase kinase (GSK)-3, and p70 ribosomal s6 kinase. PI3K also interacts directly with the cytoskeletal organizing proteins, Rac, rho, and cdc42 (Shepherd, P.R. et al. (1998) Biochem. J. 333:471-490). Animal models for diabetes, such as *obese* and *fat* mice, have altered PI3K adapter subunit levels. Specific mutations in the adapter subunit have also been found in an insulin-resistant Danish population, suggesting a role for PI3K in type-2 diabetes (Shepard, supra).

An example of lipid kinase phosphorylation activity is the phosphorylation of D-erythro-sphingosine to the sphingolipid metabolite, sphingosine-1-phosphate (SPP). SPP has emerged as a novel lipid second-messenger with both extracellular and intracellular actions (Kohama, T. et al. (1998) J. Biol. Chem. 273:23722-23728). Extracellularly, SPP is a ligand for the G-protein

coupled receptor EDG-1 (endothelial-derived, G-protein coupled receptor). Intracellularly, SPP regulates cell growth, survival, motility, and cytoskeletal changes. SPP levels are regulated by sphingosine kinases that specifically phosphorylate D-erythro-sphingosine to SPP. The importance of sphingosine kinase in cell signaling is indicated by the fact that various stimuli, including

5 platelet-derived growth factor (PDGF), nerve growth factor, and activation of protein kinase C, increase cellular levels of SPP by activation of sphingosine kinase, and the fact that competitive inhibitors of the enzyme selectively inhibit cell proliferation induced by PDGF (Kohama et al., supra).

Purine Nucleotide Kinases

10 The purine nucleotide kinases, adenylate kinase (ATP:AMP phosphotransferase, or AdK) and guanylate kinase (ATP:GMP phosphotransferase, or GuK) play a key role in nucleotide metabolism and are crucial to the synthesis and regulation of cellular levels of ATP and GTP, respectively. These two molecules are precursors in DNA and RNA synthesis in growing cells and provide the primary source of biochemical energy in cells (ATP), and signal transduction pathways (GTP). Inhibition of

15 various steps in the synthesis of these two molecules has been the basis of many antiproliferative drugs for cancer and antiviral therapy (Pillwein, K. et al. (1990) Cancer Res. 50:1576-1579).

AdK is found in almost all cell types and is especially abundant in cells having high rates of ATP synthesis and utilization such as skeletal muscle. In these cells AdK is physically associated with mitochondria and myofibrils, the subcellular structures that are involved in energy production and utilization, respectively. Recent studies have demonstrated a major function for AdK in

20 transferring high energy phosphoryls from metabolic processes generating ATP to cellular components consuming ATP (Zelevnikar, R.J. et al. (1995) J. Biol. Chem. 270:7311-7319). Thus AdK may have a pivotal role in maintaining energy production in cells, particularly those having a high rate of growth or metabolism such as cancer cells, and may provide a target for suppression of its

25 activity to treat certain cancers. Alternatively, reduced AdK activity may be a source of various metabolic, muscle-energy disorders that can result in cardiac or respiratory failure and may be treatable by increasing AdK activity.

GuK, in addition to providing a key step in the synthesis of GTP for RNA and DNA synthesis, also fulfills an essential function in signal transduction pathways of cells through the

30 regulation of GDP and GTP. Specifically, GTP binding to membrane associated G proteins mediates the activation of cell receptors, subsequent intracellular activation of adenyl cyclase, and production of the second messenger, cyclic AMP. GDP binding to G proteins inhibits these processes. GDP and GTP levels also control the activity of certain oncogenic proteins such as p21^{ras} known to be involved in control of cell proliferation and oncogenesis (Bos, J.L. (1989) Cancer Res. 49:4682-4689). High

35 ratios of GTP:GDP caused by suppression of GuK cause activation of p21^{ras} and promote

oncogenesis. Increasing GuK activity to increase levels of GDP and reduce the GTP:GDP ratio may provide a therapeutic strategy to reverse oncogenesis.

GuK is an important enzyme in the phosphorylation and activation of certain antiviral drugs useful in the treatment of herpes virus infections. These drugs include the guanine homologs acyclovir and bucidovir (Miller, W.H. and R.L. Miller (1980) J. Biol. Chem. 255:7204-7207; Stenberg, K. et al. (1986) J. Biol. Chem. 261:2134-2139). Increasing GuK activity in infected cells may provide a therapeutic strategy for augmenting the effectiveness of these drugs and possibly for reducing the necessary dosages of the drugs.

Pyrimidine Kinases

10 The pyrimidine kinases are deoxycytidine kinase and thymidine kinase 1 and 2. Deoxycytidine kinase is located in the nucleus, and thymidine kinase 1 and 2 are found in the cytosol (Johansson, M. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:11941-11945). Phosphorylation of deoxyribonucleosides by pyrimidine kinases provides an alternative pathway for *de novo* synthesis of DNA precursors. The role of pyrimidine kinases, like purine kinases, in phosphorylation is critical to
15 the activation of several chemotherapeutically important nucleoside analogues (Arner E.S. and S. Eriksson (1995) Pharmacol. Ther. 67:155-186).

The discovery of new human kinases and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, immune disorders, disorders affecting growth and development, atherosclerosis and other
20 cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

SUMMARY OF THE INVENTION

25 The invention features purified polypeptides, human kinases, referred to collectively as "PKIN" and individually as "PKIN-1," "PKIN-2," "PKIN-3," "PKIN-4," "PKIN-5," "PKIN-6," "PKIN-7," "PKIN-8," "PKIN-9," "PKIN-10," and "PKIN-11." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally
30 occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of
35 SEQ ID NO:1-11.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-11. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:12-22.

10 Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

20 The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

30 Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino

35

acid sequence selected from the group consisting of SEQ ID NO:1-11.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, b) a naturally occurring polynucleotide sequence having at least
5 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a
10 sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence
15 complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of
20 said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group
25 consisting of SEQ ID NO:12-22, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b)
30 detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino
35 acid sequence having at least 90% sequence identity to an amino acid sequence selected from the

group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence
5 selected from the group consisting of SEQ ID NO:1-11. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a)
10 an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic
15 fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another
20 alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally
25 occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic
30 fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In
another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds

to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

10 The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:12-22, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, iii) a

polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

15

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

35

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which
5 will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so
10 forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now
15 described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

20 "PKIN" refers to the amino acid sequences of substantially purified PKIN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of PKIN. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other
25 compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

An "allelic variant" is an alternative form of the gene encoding PKIN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or
30 many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PKIN include those sequences with deletions,
35 insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PKIN or a

polypeptide with at least one functional characteristic of PKIN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PKIN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding

5 PKIN. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PKIN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PKIN is retained. For example,

10 negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

15 The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

20 "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of PKIN. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small

25 molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant.

30 Antibodies that bind PKIN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin,

35 and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic PKIN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PKIN or fragments of PKIN may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied

Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and
 5 assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded
 10 as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
15	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
20	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
25	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
30	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of
 35 the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an
 40 alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative

polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

5 A "fragment" is a unique portion of PKIN or the polynucleotide encoding PKIN which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10,
10 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the
15 specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:12-22 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:12-22, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:12-22 is useful, for
20 example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:12-22 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:12-22 and the region of SEQ ID NO:12-22 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-11 is encoded by a fragment of SEQ ID NO:12-22. A fragment
25 of SEQ ID NO:1-11 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-11. For example, a fragment of SEQ ID NO:1-11 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-11. The precise length of a fragment of SEQ ID NO:1-11 and the region of SEQ ID NO:1-11 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended
30 purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between
35 two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and
 5 therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in
 10 Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

15 Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence
 20 analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
 25 programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

30 *Penalty for mismatch: -2*

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

35 *Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
5 nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes
10 in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some
15 alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e
20 sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

25 Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

30 *Open Gap: 11 and Extension Gap: 1 penalties*

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

35 Percent identity may be measured over the length of an entire defined polypeptide sequence,

for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment
5 length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

10 The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific
15 hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive
20 conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

25 Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and
30 conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS,
35 for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC

concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of PKIN which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of PKIN which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of PKIN. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PKIN.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the

antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding
5 sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
10 PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an PKIN may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will
15 vary by cell type depending on the enzymatic milieu of PKIN.

"Probe" refers to nucleic acid sequences encoding PKIN, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
20 "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous
25 nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

30 Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs
35 can be derived from a known sequence, for example, by using computer programs intended for that

purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 5 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from 10 megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection 15 programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both 20 unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

25 A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have 30 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a 35 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is

expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription,
5 translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

10 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing PKIN,
15 nucleic acids encoding PKIN, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or
20 synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

25 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides
30 by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

35 A "transcript image" refers to the collective pattern of gene expression by a particular cell

type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to

another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The
 5 presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-
 10 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

15 THE INVENTION

The invention is based on the discovery of new human human kinases (PKIN), the polynucleotides encoding PKIN, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, immune disorders, disorders affecting growth and development, atherosclerosis and other cardiovascular diseases, and lipid disorders.

20 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is
 25 denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3
 30 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

35 Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and

2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the
5 MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these
10 properties establish that the claimed polypeptides are human kinases. For example, SEQ ID NO:5 is 81% identical, from residue M1 to residue Q783, to rat salt-inducible protein kinase (GenBank ID g5672676) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is negligible, indicating the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:5 also contains protein kinase domains as
15 determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:5 is a protein kinase. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11 were analyzed and
20 annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-11 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any
combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence
25 identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:12-22 or that distinguish between SEQ ID NO:12-22 and
30 related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective
35 full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 7286907H1 is the identification number of an Incyte cDNA sequence, and BRAIFER06 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 70067849V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g6560812_002.edit is the identification number of a Genscan-predicted coding sequence, with g6560812 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL6756529_00001 represents a "stitched" sequence in which 6756529 is the identification number of the cluster of sequences to which the algorithm was applied, and 00001 is the number of the prediction generated by the algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses PKIN variants. A preferred PKIN variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the PKIN amino acid sequence, and which contains at least one functional or structural characteristic of PKIN.

The invention also encompasses polynucleotides which encode PKIN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:12-22, which encodes PKIN. The polynucleotide sequences of SEQ ID NO:12-22, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding PKIN. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PKIN. A particular aspect of the invention encompasses a variant of a
5 polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:12-22 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:12-22. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PKIN.

10 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PKIN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These
15 combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PKIN, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PKIN and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring PKIN under appropriately selected
20 conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PKIN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide
25 sequence encoding PKIN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PKIN and PKIN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the
30 synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PKIN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID
35 NO:12-22 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and

S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PKIN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National

Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PKIN may be cloned in recombinant DNA molecules that direct expression of PKIN, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PKIN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PKIN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of PKIN, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene

variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding PKIN may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser.* 7:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.) Alternatively, PKIN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of PKIN, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active PKIN, the nucleotide sequences encoding PKIN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PKIN. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PKIN. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PKIN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals

may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PKIN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PKIN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.)

The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PKIN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PKIN can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PKIN into the vector's multiple

cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PKIN are needed, e.g. for the production of antibodies, vectors which direct high level expression of PKIN may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PKIN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PKIN. Transcription of sequences encoding PKIN may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PKIN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PKIN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet.

15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PKIN in cell lines is preferred. For example, sequences encoding PKIN can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous
5 expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using
10 tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk⁻* and *apr⁻* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic,
15 or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which
20 alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.
25 (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PKIN is inserted within a marker gene sequence, transformed cells containing sequences encoding PKIN can be identified by the absence of marker gene function. Alternatively, a
30 marker gene can be placed in tandem with a sequence encoding PKIN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PKIN and that express PKIN may be identified by a variety of procedures known to those of skill in the art. These
35 procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR

amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PKIN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques
5 include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PKIN is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN,
10 Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled
15 hybridization or PCR probes for detecting sequences related to polynucleotides encoding PKIN include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PKIN, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase
20 such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

25 Host cells transformed with nucleotide sequences encoding PKIN may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PKIN may be designed to contain signal sequences which
30 direct-secretion of PKIN through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or
35 "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.

Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

5 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PKIN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PKIN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PKIN activity. Heterologous protein and
10 peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and
15 metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PKIN encoding sequence and the heterologous protein sequence, so that PKIN may be cleaved away from the heterologous moiety following purification.
20 Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PKIN may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These
25 systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

PKIN of the present invention or fragments thereof may be used to screen for compounds that specifically bind to PKIN. At least one and up to a plurality of test compounds may be screened for
30 specific binding to PKIN. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of PKIN, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2):
35 Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which PKIN

binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express PKIN, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or

5 E. coli. Cells expressing PKIN or cell membrane fractions which contain PKIN are then contacted with a test compound and binding, stimulation, or inhibition of activity of either PKIN or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example,

10 the assay may comprise the steps of combining at least one test compound with PKIN, either in solution or affixed to a solid support, and detecting the binding of PKIN to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a

15 solid support.

PKIN of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of PKIN. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for PKIN activity, wherein PKIN is combined with at least one test compound, and the activity of PKIN in the

20 presence of a test compound is compared with the activity of PKIN in the absence of the test compound. A change in the activity of PKIN in the presence of the test compound is indicative of a compound that modulates the activity of PKIN. Alternatively, a test compound is combined with an in vitro or cell-free system comprising PKIN under conditions suitable for PKIN activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of PKIN

25 may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding PKIN or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal

30 models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region

of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell
5 blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding PKIN may also be manipulated in vitro in ES cells derived from
10 human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding PKIN can also be used to create "knockin" humanized animals
15 (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding PKIN is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
20 Alternatively, a mammal inbred to overexpress PKIN, e.g., by secreting PKIN in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PKIN and human kinases. In addition, the expression of PKIN is closely
25 associated with cancer, including breast and prostate cancer. Therefore, PKIN appears to play a role in cancer, immune disorders, disorders affecting growth and development, atherosclerosis and other cardiovascular diseases, and lipid disorders. In the treatment of disorders associated with increased PKIN expression or activity, it is desirable to decrease the expression or activity of PKIN. In the treatment of disorders associated with decreased PKIN expression or activity, it is desirable to
30 increase the expression or activity of PKIN.

Therefore, in one embodiment, PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in
35 particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall

bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome,

5 allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's

10 syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome,

15 complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma,

20 leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy,

25 gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and

30 sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease,

35 degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve,

mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity.

In another embodiment, a vector capable of expressing PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified PKIN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PKIN may be administered to a subject to treat or prevent a disorder associated with decreased expression or

activity of PKIN including, but not limited to, those listed above.

In a further embodiment, an antagonist of PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN. Examples of such disorders include, but are not limited to, those cancer, immune disorders, disorders affecting growth and development, atherosclerosis and other cardiovascular diseases, and lipid disorders, described above. In one aspect, an antibody which specifically binds PKIN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PKIN.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PKIN may be produced using methods which are generally known in the art. In particular, purified PKIN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PKIN. Antibodies to PKIN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PKIN or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PKIN have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or

fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of PKIN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PKIN may be prepared using any technique which provides for the
5 production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

10 In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single
15 chain antibodies may be adapted, using methods known in the art, to produce PKIN-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte
20 population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for PKIN may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin
25 digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired
30 specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PKIN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PKIN epitopes is generally used, but a competitive binding assay may
35 also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PKIN. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of PKIN-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.

5 The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PKIN epitopes, represents the average affinity, or avidity, of the antibodies for PKIN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PKIN epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the

10 PKIN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PKIN, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons,

15 New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation

20 of PKIN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PKIN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene

25 expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding PKIN. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PKIN. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

30 In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995)

35 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral

vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding PKIN may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA.* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in PKIN expression or regulation causes disease, the expression of PKIN from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in PKIN are treated by constructing mammalian expression vectors encoding PKIN and introducing these vectors by mechanical means into PKIN-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of PKIN include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA),

PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). PKIN may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. *supra*)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding PKIN from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to PKIN expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding PKIN under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in

the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

5 In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding PKIN to cells which have one or more genetic abnormalities with respect to the expression of PKIN. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas
10 (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

15 In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding PKIN to target cells which have one or more genetic abnormalities with respect to the expression of PKIN. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing PKIN to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with
20 ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant
25 HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned
30 herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

 In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to
35 deliver polynucleotides encoding PKIN to target cells. The biology of the prototypic alphavirus,

Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for PKIN into the alphavirus genome in place of the capsid-coding region results in the production of a large number of PKIN-coding RNAs and the synthesis of high levels of PKIN in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of PKIN into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PKIN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for

secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared
5 by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PKIN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs
10 that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase
15 linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

20 An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding PKIN. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular
25 chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased PKIN expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding PKIN may be therapeutically useful, and in the treatment of disorders associated with
30 decreased PKIN expression or activity, a compound which specifically promotes expression of the polynucleotide encoding PKIN may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in
35 altering polynucleotide expression; selection from an existing, commercially-available or proprietary

library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding PKIN is exposed to at least one test compound thus obtained. The sample
5 may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding PKIN are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding PKIN. The amount of hybridization may be quantified, thus forming
10 the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system
15 (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide
20 sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.
25 Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and
30 monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of
35 Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may

consist of PKIN, antibodies to PKIN, and mimetics, agonists, antagonists, or inhibitors of PKIN.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising PKIN or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, PKIN or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PKIN or fragments thereof, antibodies of PKIN, and agonists, antagonists or inhibitors of PKIN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large

therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu\text{g}$ to $100,000 \mu\text{g}$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind PKIN may be used for the diagnosis of disorders characterized by expression of PKIN; or in assays to monitor patients being treated with PKIN or agonists, antagonists, or inhibitors of PKIN. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PKIN include methods which utilize the antibody and a label to detect PKIN in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PKIN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PKIN expression. Normal or standard values for PKIN expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to PKIN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of PKIN expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PKIN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of PKIN may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PKIN, and to monitor regulation of PKIN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PKIN or closely related molecules may be used to identify nucleic acid sequences which encode PKIN. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding PKIN, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PKIN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:12-22 or from genomic sequences including promoters, enhancers, and introns of the PKIN gene.

Means for producing specific hybridization probes for DNAs encoding PKIN include the cloning of polynucleotide sequences encoding PKIN or PKIN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PKIN may be used for the diagnosis of disorders associated with expression of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's

disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or

5 pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental

10 disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,

15 gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial

20 dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins,

25 thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease,

30 infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive

35 pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease,

emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity. The polynucleotide sequences encoding PKIN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PKIN expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PKIN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PKIN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PKIN in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PKIN, a normal or standard profile for expression is established. This may be accomplished by combining

body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PKIN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PKIN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PKIN, or a fragment of a polynucleotide complementary to the polynucleotide encoding PKIN, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the

oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus

5 sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of PKIN include radiolabeling or
10 biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives
15 rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify
20 genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and
25 effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, PKIN, fragments of PKIN, or antibodies specific for PKIN may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein
30 interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at
35 a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number

5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples

are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for PKIN to quantify the levels of PKIN expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoze, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which

alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding PKIN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet.

7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

5 Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PKIN on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the
10 region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is
15 valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of
20 the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

 In another embodiment of the invention, PKIN, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug-screening techniques. The fragment employed in such screening may be free in solution, affixed to a
25 solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PKIN and the agent being tested may be measured.

 Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are
30 synthesized on a solid substrate. The test compounds are reacted with PKIN, or fragments thereof, and washed. Bound PKIN is then detected by methods well known in the art. Purified PKIN can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

 In another embodiment, one may use competitive drug screening assays in which neutralizing
35 antibodies capable of binding PKIN specifically compete with a test compound for binding PKIN. In

this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PKIN.

In additional embodiments, the nucleotide sequences which encode PKIN may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Serial No. 60/183,682, U.S. Serial No. 60/186,559, U.S. Serial No. 60/188,606, U.S. Serial No. 60/189,998, and U.S. Serial No. 60/193,851, are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic

oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI

protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

- 5 The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and
- 10 BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.
- 15 Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive
- 20 the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length
- 25 polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
- 30 Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column
- 35 presents, where applicable, the scores, probability values, and other parameters used to evaluate the

strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ
5 ID NO:12-22. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative human kinases were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-
10 purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a
15 FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode human kinases, the encoded polypeptides were analyzed by querying against
PFAM models for human kinases. Potential human kinases were also identified by homology to
Incyte cDNA sequences that had been annotated as human kinases. These selected Genscan-
predicted sequences were then compared by BLAST analysis to the genpept and gbpri public
20 databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available, this information was used to correct or confirm the Genscan predicted
25 sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

30 "Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm
35 based on graph theory and dynamic programming to integrate cDNA and genomic information,

generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

15 **"Stretched" Sequences**

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of PKIN Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:12-22 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:12-22 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences

had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, or human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

In this manner, SEQ ID NO:20 was mapped to chromosome 1 within the interval from 75.30 to 81.60 centiMorgans.

15 VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

20 Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

25

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate

the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding PKIN are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding PKIN. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of PKIN Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$,

and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the
5 alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
10 and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the
15 sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For
20 shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in
25 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was
30 quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

35 In like manner, full length polynucleotide sequences are verified using the above procedure or

are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:12-22 are employed to screen cDNAs,
5 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase
10 (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

15 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and
20 compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the
25 aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to
30 those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be
35 selected using software well known in the art such as LASERGENE software (DNASTAR). The

array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

10 Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse
15 transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified
20 using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

25 Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5
30 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR

Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 µl of the array element DNA, at an average concentration of 100 ng/µl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.

Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 µl of sample mixture consisting of 0.2 µg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 µl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The

emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the PKIN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PKIN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PKIN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PKIN-encoding transcript.

XII. Expression of PKIN

Expression and purification of PKIN is achieved using bacterial or virus-based expression systems. For expression of PKIN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA

transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express PKIN upon induction with isopropyl beta-D-

5 thiogalactopyranoside (IPTG). Expression of PKIN in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PKIN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong
10 polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

15 In most expression systems, PKIN is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham
20 Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PKIN at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995,
25 supra, ch. 10 and 16). Purified PKIN obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

PKIN function is assessed by expressing the sequences encoding PKIN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression
30 vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a
35 marker protein are co-transfected. Expression of a marker protein provides a means to distinguish

transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PKIN on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PKIN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PKIN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of PKIN Specific Antibodies

PKIN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PKIN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for

antipeptide and anti-PKIN activity by, for example, binding the peptide or PKIN to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring PKIN Using Specific Antibodies

5 Naturally occurring or recombinant PKIN is substantially purified by immunoaffinity chromatography using antibodies specific for PKIN. An immunoaffinity column is constructed by covalently coupling anti-PKIN antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

10 Media containing PKIN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PKIN (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PKIN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PKIN is collected.

15 XVI. Identification of Molecules Which Interact with PKIN

PKIN, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PKIN, washed, and any wells with labeled PKIN complex are assayed. Data obtained using different concentrations
20 of PKIN are used to calculate values for the number, affinity, and association of PKIN with the candidate molecules.

Alternatively, molecules interacting with PKIN are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

25 PKIN may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of PKIN Activity

30 Generally, protein kinase activity is measured by quantifying the phosphorylation of a protein substrate by PKIN in the presence of gamma-labeled ^{32}P -ATP. PKIN is incubated with the protein substrate, ^{32}P -ATP, and an appropriate kinase buffer. The ^{32}P incorporated into the substrate is separated from free ^{32}P -ATP by electrophoresis and the incorporated ^{32}P is counted using a radioisotope counter. The amount of incorporated ^{32}P is proportional to the activity of PKIN. A
35 determination of the specific amino acid residue phosphorylated is made by phosphoamino acid

analysis of the hydrolyzed protein.

In one alternative, protein kinase activity is measured by quantifying the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. The reaction occurs between a protein kinase sample with a biotinylated peptide substrate and gamma ^{32}P -ATP. Following the reaction, free avidin in solution is added for binding to the biotinylated ^{32}P -peptide product. The binding sample then undergoes a centrifugal ultrafiltration process with a membrane which will retain the product-avidin complex and allow passage of free gamma ^{32}P -ATP. The reservoir of the centrifuged unit containing the ^{32}P -peptide product as retentate is then counted in a scintillation counter. This procedure allows assay of any type of protein kinase sample, depending on the peptide substrate and kinase reaction buffer selected. This assay is provided in kit form (ASUA, Affinity Ultrafiltration Separation Assay, Transbio Corporation, Baltimore MD, U.S. Patent No. 5,869,275). Suggested substrates and their respective enzymes are as follows: Histone H1 (Sigma) and p34^{cdc2}kinase, Annexin I, Angiotensin (Sigma) and EGF receptor kinase, Annexin II and *src* kinase, ERK1 & ERK2 substrates and MEK, and myelin basic protein and ERK (Pearson, J.D. et al. (1991) Methods Enzymol. 200:62-81).

In another alternative, protein kinase activity of PKIN is demonstrated in vitro in an assay containing PKIN, 50 μl of kinase buffer, 1 μg substrate, such as myelin basic protein (MBP) or synthetic peptide substrates, 1 mM DTT, 10 μg ATP, and 0.5 μCi [γ - ^{33}P]ATP. The reaction is incubated at 30°C for 30 minutes and stopped by pipetting onto P81 paper. The unincorporated [γ - ^{33}P]ATP is removed by washing and the incorporated radioactivity is measured using a radioactivity scintillation counter. Alternatively, the reaction is stopped by heating to 100°C in the presence of SDS loading buffer and visualized on a 12% SDS polyacrylamide gel by autoradiography. Incorporated radioactivity is corrected for reactions carried out in the absence of PKIN or in the presence of the inactive kinase, K38A.

In yet another alternative, adenylate kinase or guanylate kinase activity may be measured by the incorporation of ^{32}P from gamma-labeled ^{32}P -ATP into ADP or GDP using a gamma radioisotope counter. The enzyme, in a kinase buffer, is incubated together with the appropriate nucleotide mono-phosphate substrate (AMP or GMP) and ^{32}P -labeled ATP as the phosphate donor. The reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected to gel electrophoresis to separate the mono-, di-, and triphosphonucleotide fractions. The diphosphonucleotide fraction is cut out and counted. The radioactivity recovered is proportional to the enzyme activity.

In yet another alternative, other assays for PKIN include scintillation proximity assays (SPA), scintillation plate technology and filter binding assays. Useful substrates include recombinant proteins tagged with glutathione transferase, or synthetic peptide substrates tagged with biotin.

Inhibitors of PKIN activity, such as small organic molecules, proteins or peptides, may be identified by such assays.

XVIII. Enhancement/Inhibition of Protein Kinase Activity

Agonists or antagonists of PKIN activation or inhibition may be tested using assays described
5 in section XVII. Agonists cause an increase in PKIN activity and antagonists cause a decrease in PKIN activity.

Various modifications and variations of the described methods and systems of the invention
will be apparent to those skilled in the art without departing from the scope and spirit of the
10 invention. Although the invention has been described in connection with certain embodiments, it
should be understood that the invention as claimed should not be unduly limited to such specific
embodiments. Indeed, various modifications of the described modes for carrying out the invention
which are obvious to those skilled in molecular biology or related fields are intended to be within the
scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
4912053	1	4912053CD1	12	4912053CB1
870615	2	870615CD1	13	870615CB1
2762870	3	2762870CD1	14	2762870CB1
5507012	4	5507012CD1	15	5507012CB1
6756529	5	6756529CD1	16	6756529CB1
387382	6	387382CD1	17	387382CB1
5850786	7	5850786CD1	18	5850786CB1
7182343	8	7182343CD1	19	7182343CB1
7264345	9	7264345CD1	20	7264345CB1
7472328	10	7472328CD1	21	7472328CB1
1471412	11	1471412CD1	22	1471412CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	4912053CD1	g190660	1.0e-06	Protein-serine kinase [Homo sapiens]
2	870615CD1	g340026	1.00E-19	Tyrosine kinase [Homo sapiens] Takahashi, M. and Cooper, G.M. (1987) Mol. Cell. Biol. 7:1378-1385.
3	2762870CD1	g4376414	5.9e-31	Serine/Threonine Protein Kinase [Chlamydomonadales]
4	5507012CD1	g4995303	1.6e-134	putative mitogen-activated protein kinase kinase kinase [Homo sapiens]
		g8272557	0.0	protein kinase WNK1 [Rattus norvegicus]
5	6756529CD1	g5672676	0.0	Xu, B. et al. (2000) J. Biol. Chem. 275:16795-16801. salt-inducible protein kinase [Rattus norvegicus]
6	387382CD1	g4519166	6.5e-209	GSG2 [Mus musculus] Tanaka, H. et al. (1994) FEBS Lett. 355: 4-10.
7	5850786CD1	g4101587	2.1e-133	serine/threonine kinase [Homo sapiens]
8	7182343CD1	g7649810 g182571	0 3.6e-34	protein kinase PAK5 [Homo sapiens] fibroblast growth factor receptor 4 [Homo sapiens]
9	7264345CD1	g4753775	3.7e-300	protein kinase [Homo sapiens] Rosok, O. et al. (1999) Genomics 61: 44-54
10	7472328CD1	g4827159	3.9e-110	kinase [Rattus sp.] Matsuda, K.M. et al. (1999) Biochem. Biophys. Res. Commun. 258: 260-264
11	1471412CD1	g2393890	1.8e-26	protein kinase homolog [Fowlpox virus]

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	4912053CD1	792	S9 T19 S66 T104 T260 T303 T471 T521 S523 T542 T585 T623 S540 S30 T172 S346 T418 T575 T600 T628	N46 N493 N589 N631 N779	PROTEIN SCY1: PD043026: T193-H469 Eukaryotic protein kinase domain: V20-F186 Tyrosine kinase catalytic domain signature: PR00109: I27-L45, S106-V128	BLAST-PRODOR HMMER-PFAM BLIMPS-PRINTS
2	870615CD1	224	S19 T50 S214 T128 S131 S191 T120 S132 T134 T147 S210 T227 S234 T270 S311 S323	N156	Domain found in NIK1-like kinase: PF00780:E169-V177 Signal peptide: M1-A32 Signal cleavage: M1-S34 PROTEIN KINASE YFMG SERINE/THREONINE SERINE/THREONINE PROTEIN KINASE [Chlamydomophila pneumoniae]: PD017761: W179-D368	BLIMPS-PFAM HMMER SPSCAN BLAST-PRODOR
3	2762870CD1	374		N141		
4	5507012CD1	565	T60 T258 S378 T436 S29 S34 T73 T91 T160 S174 S189 T243 T258 S469 T48 S231 S260 T290 T308 S363 T373 Y468	N27 N89	Serine/Threonine protein kinases active-site signature: I345-I357 Eukaryotic protein kinase domain: L221-F479 Protein_kinases_tyrosine signature and profile: I324-F379 Tyrosine kinase catalytic domain signature: PR00109A:T301-K314; PR00109B: H339-I357; PR00109C: V403-C425; PR00109D: A448-I470 Protein Kinase Domain: DM00004 S49611 39-259:I227-V447	MOTIFS HMMER-PFAM PROFILES-PRINTS BLIMPS-PRINTS BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5	6756529CD1	783	T268 T473 S575 T594 T61 S66 S122 S135 S370 S438 T473 S498 T503 S567 S649 T231 T468 S478 T593 Y114	N328	Protein kinases ATP-binding region signature: L33-K56 Serine/Threonine protein kinases active-site signature: I145-L157 Eukaryotic protein kinase domain: Y27-M278, Y304-E343, V397-S424 Protein_kinases_tyrosine signature and profile D97-G177 Tyrosine kinase catalytic domain signature: PR00109A: T103-T116; PR00109B: Y139-L157; PR00109C: I205-P227 Protein Kinase Domain: DM00004 P27448 58-297;R31-I269	MOTIFS MOTIFS HMMER-PFAM PROFILESCAN
6	387382CD1	798	T295 S458 S661 S53 S58 T181 S220 T253 S299 S458 T501 T528 S586 S684 S691 S705 S786 T97 T112 S143 S240 T289 S336 S337 S353 S421 S453 S468 T481 S582 T624 S642 T749 T757 Y739	N45 N427 N522 N551 N581 N783	Protein_Kinase_Atp: I490-K511 Eukaryotic protein kinase domain: L484-I513 KINASE TRANSFERASE: PD02952B:L643-L656	MOTIFS HMMER-PFAM BLIMPS-PRODOR

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7	5850786CD1	632	S104 S15 T23 S133 T137 S201 S226 S253 S260 S345 S418 S441 T603 S99 T143 T281 T467 T471 S599 Y152 Y182	N91 N274	Protein_Kinase_Atp: I455-K478 Eukaryotic protein kinase domain: L449-V582, L586-L613 P21-Rho-binding domain: I11-T69 Tyrosine kinase catalytic domain: PR00109B:Y558-L576 PROTEIN KINASE DOMAIN DM00004 P35465 271-510:F452-F612 DM00004 I49376 270-509:K454-F612 DM00004 Q03497 622-861:N451-F612 DM00004 P50527 388-627:N451-F589 Transmembrane domain: V226-C245 Immunoglobulin domain: G11-V69, G107-G186 Receptor tyrosine kinase: BL00240B L16-R39 BASIC FIBROBLAST GROWTH FACTOR RECEPTOR DM01287 S42803 1-713:M1-R264 DM01287 S19947 1-822:M1-R264 DM01287 A60350 1-800:M1-Q303 DM01287 JC1450 1-650:M1-P203 Protein_Kinase_Atp: I64-K87 Protein_Kinase_Tyr: I172-I184 Eukaryotic protein kinase domain: E62-I305 Protein kinases signatures and profile: V152-D206 Tyrosine kinase catalytic domain: PR00109A:T130-D143, PR00109B:Y166-I184 PR00109C:G218-L228, PR00109D:A237-Y259, PR00109E:C280-F302 PROTEIN KINASE DOMAIN DM00004 I48737 341-596:E62-F302 DM00004 P53667 340-596:E62-F302 DM00004 P53666 332-593:E62-F273 DM00004 S49313 23-266:D58-F302	MOTIFS HMMER-PFAM HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO HMMER HMMER-PFAM BLIMPS-BLOCKS BLAST-DOMO MOTIFS MOTIFS HMMER-PFAM PROFILES-SCAN BLIMPS-PRINTS BLAST-DOMO
8	7182343CD1	350	T51 T38 T102 S140 S159 T268 S336 S13 S53 S62 T66 S70 T79 S193 Y65 Y182	N77 N101 N139		
9	7264345CD1	571	S8 S345 T54 S301 T308 S345 S346 S367 S381 S477 S4 S42 S93 T151 T178 S211 T330 S373 T396 S403 S488 Y191 Y259	N31		

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10	7472328CD1	323	T54 T90 T140 T175 S180 S14 T27 T95 T159 S197 S203		Eukaryotic protein kinase domain: P188-L280 PROTEIN KINASE DOMAIN DM00004 S56719 7-251:P188-T270 DM00004 S52244 15-255:A154-T270 DM00004 S24578 18-262:K184-T270 DM00004 P34244 82-359:K184-T270	HMMER-PFAM BLAST-DOMO
11	1471412CD1	471	S106 S467 T290 T363 S378 S458 S55 S80 S161 T175 T253 T368 S417 S454 Y23	N81	Eukaryotic protein kinase domain: Y218-K464 Tyrosine kinase catalytic domain signature PR00109: M283-D296; S393-C415; C437-V459 PROTEIN KINASE DOMAIN DM00004 JQ1743 73-262: N261-V459	HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
12	4912053CB1	4335	1-592, 4026-4335, 3351-3496, 1123-2842	70067849V1	1715	2313
				7286907H1 (BRAIFER06)	784	1323
				4912053H1 (THYMDIT01)	230	514
				2659638F6 (LUNGUT09)	3361	3875
				2545191T6 (UTRSNOT11)	3666	4131
				1406536F6 (LATRTUT02)	2478	2996
				2545191F6 (UTRSNOT11)	3064	3477
				70066706V1	1854	2419
				6526407H1 (CONFNOT07)	1315	1855
				6916054H1 (PLACFER06)	256	845
				2874082T6 (THYRNOT10)	2717	3334
				GNN.g6560812_002.edit	1	546
13	870615CB1	1829	800-877, 531-669, 1-456, 703-763	2550210F6 (LUNGUT06)	3837	4335
				2874082F6 (THYRNOT10)	1143	1756
				70063710V1	2321	2841
				6583325H1 (LUNGFEC01)	1	597
				70882046V1	620	1201
				70885573V1	558	1169
				2172659F6 (ENDCNOT03)	1576	1828
14	2762870CB1	2143	1-1269	70485671V1	1237	1729
				70483457V1	1115	1655
				7151622H1 (BONEUNR01)	646	1168
				6308250H1 (NERDTDN03)	410	972
				6545148H1 (LNODNON02)	1201	1762
				4298443H1 (SCOMDIT01)	1888	2143
				4548711T1 (HELAUNT01)	1474	2117
				6486245H1 (MIXDUNB01)	993	1599
				6780258H1 (OVARDIR01)	1	572
				2058456R6 (OVARNOT03)	1772	2126

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
15	5507012CB1	2310	1-158, 1433-1571, 671-802	70294304D1	1809	2231
				7312202H1	1	380
				6771174J1 (BRAUNOR01)	770	1529
				6808373H1 (SKIRNOR01)	359	865
				70425501D1	1883	2310
16	6756529CB1	4699	3346-3845, 1-2800	7088726H1 (BRAUTDR03)	1511	2094
				1926322R6 (BRSTNOT02)	4366	4699
				6932134H1 (SINTTMR02)	1	701
				1963560R6 (BRSTNOT04)	3544	4057
				1861375H1 (PROSNOT19)	3510	3778
				FL6756529_00001	664	3008
				1858047H1 (PROSNOT18)	3218	3497
				1995450T6 (BRSTTUT03)	3966	4672
				1657259H1 (URETTUT01)	3063	3243
				5617980H1 (THYMNOR02)	2724	3019
				3330722H1 (HEAONOT04)	3272	3551
				1699226F6 (BLADTUT05)	4259	4679
17	387382CB1	2649	1-372, 2629-2649, 590-1733	1746121H1 (STOMTUT02)	2959	3239
				387382T6 (THYMNOR02)	2381	2649
				7159938H1 (HNT2TXC01)	1750	2310
				2047113H1 (THP1T7T01)	1562	1939
				4849452F9 (SPLNTUT02)	1	303
				GNN.g6006112_000006_002	17	2448
				387382R6 (THYMNOR02)	1937	2649
				5262448T6 (CONDUTUT02)	1824	2519
				5262448F6 (CONDUTUT02)	1	493
				71193135V1	539	1251
18	5850786CB1	2526	1903-1997, 562-1537	71198067V1	2173	2526
				71191147V1	421	1024
				71189347V1	1291	1999
				71391065V1	1219	1887

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
19	7182343CB1	2178	1-682, 1280-1431	70647146V1	1100	1778
				7182637H1 (BONRFEC01)	1155	1801
				7358741H1	613	1156
				7182343H1 (BONRFEC01)	1	503
				6951475H1 (BRAITDR02)	193	807
20	7264345CB1	2777	1710-2038, 651-1227, 354-393	70676086V1	1622	2178
				7264345H1 (PROSTMC02)	580	1154
				70003406D1	708	1372
				6609118H2 (PLACFEC01)	1	597
				70003129D1	2280	2777
				71111386V1	1813	2512
				7014503H1 (KIDNNOC01)	1988	2547
				70384792D1	1183	1702
				70006067D1	1360	1908
				GNN.g6249409_000023_002	1	972
21	7472328CB1	972	444-467	135966T6 (BMARNOT02)	1820	2514
22	1471412CB1	2538	547-1835 1-113	70162584V1	1085	1758
				70604897V1	1001	1650
				2489917R6 (BRAVUNT02)	1	468
				5504821R6 (BRADDIR01)	363	996
				4741826R8 (THYMNOR02)	483	1073
				70608907V1	2019	2538
				70162579V1	1687	2311

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
12	4912053CB1	UCMCNOT02
13	870615CB1	BRABDIR01
14	2762870CB1	BRSTTUT03
15	5507012CB1	BRAUNOR01
16	6756529CB1	BLADNOT09
17	387382CB1	THYMNOT02
18	5850786CB1	CONDUTUT02
19	7182343CB1	FTUBTUR01
20	7264345CB1	EOSIHET02
22	1471412CB1	PROSTUS23

Table 6

Library	Vector	Library Description
BRABDIR01	pINCY	Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and tobacco abuse.
UCMCNOT02	pINCY	Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of nine individuals.
BRSTTUT03	PSPORT1	Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast.
BLADNOT09	pINCY	Library was constructed using RNA isolated from bladder tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, regional lymph node excision, and urinary diversion to bowel. Pathology for the associated tumor tissue indicated invasive grade 3 transitional cell carcinoma. Patient history included a benign colon neoplasm.
BRAUNOR01	pINCY	This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloidal goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease.

Table 6 (cont.)

Library	Vector	Library Description
CONDUTUT02	pINCY	Library was constructed using RNA isolated from peritoneal tumor tissue removed from a 66-year-old Caucasian female during exploratory laparotomy. Pathology indicated neuroendocrine carcinoma involving the anterior peritoneum, right ovary and fallopian tube, appendix, omentum, left diaphragm, and the small bowel, sigmoid, and uterine serosa. The uterus contained an endometrial polyp and calcified leiomyoma. Multiple lymph nodes were positive for tumor. Patient history included melanosis coli.
EOSIHT02	PBLUESCRIPT	The library was constructed using RNA isolated from peripheral blood cells adhered from a 48-year-old Caucasian male. Patient history included hypereosinophilia. The cell population was determined to be greater than 77% eosinophils by Wright's staining.
F'TUBTUR01	PCDNA2.1	This random primed library was constructed using RNA isolated from fallopian tube tumor tissue removed from an 85-year-old Caucasian female during bilateral salpingo-oophorectomy and hysterectomy. Pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma, which was confined to the mucosa without mural involvement. Endometrioid carcinoma in situ was also present. Pathology for the associated uterus tumor indicated focal endometrioid adenocarcinoma in situ and moderately differentiated invasive adenocarcinoma arising in an endometrial polyp. Metastatic endometrioid and serous adenocarcinoma was present at the cul-de-sac tumor. Patient history included medullary carcinoma of the thyroid and myocardial infarction.
THYMN0T02	PBLUESCRIPT	Library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from drowning.
PROSTUS23	pINCY	This subtracted prostate tumor library was constructed using 1 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 1 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C), and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate stroma from 3 different donors. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991):1954 and Bonaldo, et al. Genome Research 6 (1996):791.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, ffasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribkov, M. et al. (1988) CABIOS 4:61-66; Gribkov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score>GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-11,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-11,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11, and
 - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-11.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-11.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:12-22.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
- 25 7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method for producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
- 5 11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22,
 - b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:12-22,
 - 10 c) a polynucleotide sequence complementary to a),
 - d) a polynucleotide sequence complementary to b), and
 - e) an RNA equivalent of a)-d).
- 15 12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.
13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides
 - 20 comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
 - b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 25 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
- 30 a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
 - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence
5 selected from the group consisting of SEQ ID NO:1-11.

18. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition of claim 16.
10

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

15

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of
20 functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- 25 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.
30

24. A method for treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim

1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the

amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

<110> INCYTE GENOMICS, INC.
 TANG, Y. Tom
 BURFORD, Neil
 GHANDI, Aameena R.
 PATTERSON, Chandra
 KHAN, Farrah A.
 YUE, Henry
 HAFALIA, April
 SHIH, Leo L.
 TRIBOULEY, Catherine M.
 YAO, Monique G.
 BURRILL, John D.
 MARCUS, Gregory A.
 ZINGLER, Kurt A.
 LU, Dyung Aina M.
 BANDMAN, Olga
 POLICKY, Jennifer L.
 GRIFFIN, Jennifer A.
 THORNTON, Michael
 NGUYEN, Dannel B.
 LAL, Preeti
 WALSH, Roderick T.

<120> HUMAN KINASES

<130> PI-0037 PCT

<140> To Be Assigned

<141> Herewith

<160> 22

<170> PERL Program

<210> 1

<211> 792

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4912053CD1

<400> 1

Met	Lys	Glu	His	Phe	Phe	Ser	Ala	Ser	Phe	Ser	Asp	Thr	Lys	Leu
1				5					10					15
Lys	Pro	Gly	Thr	Val	Ser	Glu	Gly	Leu	Ser	Phe	Leu	His	Ser	Ser
				20					25					30
Val	Lys	Met	Val	His	Gly	Asn	Ile	Thr	Pro	Glu	Asn	Ile	Ile	Leu
				35					40					45
Asn	Lys	Ser	Gly	Ala	Trp	Lys	Ile	Met	Gly	Phe	Asp	Phe	Cys	Val
				50					55					60
Ser	Ser	Thr	Asn	Pro	Ser	Glu	Gln	Glu	Pro	Lys	Phe	Pro	Cys	Lys
				65					70					75
Glu	Trp	Asp	Pro	Asn	Leu	Pro	Ser	Leu	Cys	Leu	Pro	Asn	Pro	Glu
				80					85					90
Tyr	Leu	Ala	Pro	Glu	Tyr	Ile	Leu	Ser	Val	Ser	Cys	Glu	Thr	Ala
				95					100					105
Ser	Asp	Met	Tyr	Ser	Leu	Gly	Thr	Val	Met	Tyr	Ala	Val	Phe	Asn
				110					115					120
Lys	Gly	Lys	Pro	Ile	Phe	Glu	Val	Asn	Lys	Gln	Asp	Ile	Tyr	Lys
				125					130					135
Ser	Phe	Ser	Arg	Gln	Leu	Asp	Gln	Leu	Ser	Arg	Leu	Gly	Ser	Ser
				140					145					150

Ser	Leu	Thr	Asn	Ile	Pro	Glu	Glu	Val	Arg	Glu	His	Val	Lys	Leu
				155					160					165
Leu	Leu	Asn	Val	Thr	Pro	Thr	Val	Arg	Pro	Asp	Ala	Asp	Gln	Met
				170					175					180
Thr	Lys	Ile	Pro	Phe	Phe	Asp	Asp	Val	Gly	Ala	Val	Thr	Leu	Gln
				185					190					195
Tyr	Phe	Asp	Thr	Leu	Phe	Gln	Arg	Asp	Asn	Leu	Gln	Lys	Ser	Gln
				200					205					210
Phe	Phe	Lys	Gly	Leu	Pro	Lys	Val	Leu	Pro	Lys	Leu	Pro	Lys	Arg
				215					220					225
Val	Ile	Val	Gln	Arg	Ile	Leu	Pro	Cys	Leu	Thr	Ser	Glu	Phe	Val
				230					235					240
Asn	Pro	Asp	Met	Val	Pro	Phe	Val	Leu	Pro	Asn	Val	Leu	Leu	Ile
				245					250					255
Ala	Glu	Glu	Cys	Thr	Lys	Glu	Glu	Tyr	Val	Lys	Leu	Ile	Leu	Pro
				260					265					270
Glu	Leu	Gly	Pro	Val	Phe	Lys	Gln	Gln	Glu	Pro	Ile	Gln	Ala	Ser
				275					280					285
Asn	Met	Ile	Leu	Leu	Ile	Phe	Leu	Gln	Lys	Met	Asp	Leu	Leu	Leu
				290					295					300
Thr	Lys	Thr	Pro	Pro	Asp	Glu	Ile	Lys	Asn	Ser	Val	Leu	Pro	Met
				305					310					315
Val	Tyr	Arg	Ala	Leu	Glu	Ala	Pro	Ser	Ile	Gln	Ile	Gln	Glu	Leu
				320					325					330
Cys	Leu	Asn	Ile	Ile	Pro	Thr	Phe	Ala	Asn	Leu	Ile	Asp	Tyr	Pro
				335					340					345
Ser	Met	Lys	Asn	Ala	Leu	Ile	Pro	Arg	Ile	Lys	Asn	Ala	Cys	Leu
				350					355					360
Gln	Thr	Ser	Ser	Leu	Ala	Val	Arg	Val	Asn	Ser	Leu	Val	Cys	Leu
				365					370					375
Gly	Lys	Ile	Leu	Glu	Tyr	Leu	Asp	Lys	Trp	Phe	Val	Leu	Asp	Asp
				380					385					390
Ile	Leu	Pro	Phe	Leu	Gln	Gln	Ile	Pro	Ser	Lys	Glu	Pro	Ala	Val
				395					400					405
Leu	Met	Gly	Ile	Leu	Gly	Ile	Tyr	Lys	Cys	Thr	Phe	Thr	His	Lys
				410					415					420
Lys	Leu	Gly	Ile	Thr	Lys	Glu	Gln	Leu	Ala	Gly	Lys	Val	Leu	Pro
				425					430					435
His	Leu	Ile	Pro	Leu	Ser	Ile	Glu	Asn	Asn	Leu	Asn	Leu	Asn	Gln
				440					445					450
Phe	Asn	Ser	Phe	Ile	Ser	Val	Ile	Lys	Glu	Met	Leu	Asn	Arg	Leu
				455					460					465
Glu	Ser	Glu	His	Lys	Thr	Lys	Leu	Glu	Gln	Leu	His	Ile	Met	Gln
				470					475					480
Glu	Gln	Gln	Lys	Ser	Leu	Asp	Ile	Gly	Asn	Gln	Met	Asn	Val	Ser
				485					490					495
Glu	Glu	Met	Lys	Val	Thr	Asn	Ile	Gly	Asn	Gln	Gln	Ile	Asp	Lys
				500					505					510
Val	Phe	Asn	Asn	Ile	Gly	Ala	Asp	Leu	Leu	Thr	Gly	Ser	Glu	Ser
				515					520					525
Glu	Asn	Lys	Glu	Asp	Gly	Leu	Gln	Asn	Lys	His	Lys	Arg	Ala	Ser
				530					535					540
Leu	Thr	Leu	Glu	Glu	Lys	Gln	Lys	Leu	Ala	Lys	Glu	Gln	Glu	Gln
				545					550					555
Ala	Gln	Lys	Leu	Lys	Ser	Gln	Gln	Pro	Leu	Lys	Pro	Gln	Val	His
				560					565					570
Thr	Pro	Val	Ala	Thr	Val	Lys	Gln	Thr	Lys	Asp	Leu	Thr	Asp	Thr
				575					580					585
Leu	Met	Asp	Asn	Met	Ser	Ser	Leu	Thr	Ser	Leu	Ser	Val	Ser	Thr
				590					595					600
Pro	Lys	Ser	Ser	Ala	Ser	Ser	Thr	Phe	Thr	Ser	Val	Pro	Ser	Met
				605					610					615
Gly	Ile	Gly	Met	Met	Phe	Ser	Thr	Pro	Thr	Asp	Asn	Thr	Lys	Arg

Asn	Leu	Thr	Asn	620	Gly	Leu	Asn	Ala	Asn	625	Met	Gly	Phe	Gln	Thr	630	Ser
Gly	Phe	Asn	Met	635	Pro	Val	Asn	Thr	Asn	640	Gln	Asn	Phe	Tyr	Ser	645	Ser
Pro	Ser	Thr	Val	650	Gly	Val	Thr	Lys	Met	655	Thr	Leu	Gly	Thr	Pro	660	Pro
Thr	Leu	Pro	Asn	665	Phe	Asn	Ala	Leu	Ser	670	Val	Pro	Pro	Ala	Gly	675	Ala
Lys	Gln	Thr	Gln	680	Gln	Arg	Pro	Thr	Asp	685	Met	Ser	Ala	Leu	Asn	690	Asn
Leu	Phe	Gly	Pro	695	Gln	Lys	Pro	Lys	Val	700	Ser	Met	Asn	Gln	Leu	705	Ser
Gln	Gln	Lys	Pro	710	Asn	Gln	Trp	Leu	Asn	715	Gln	Phe	Val	Pro	Pro	720	Gln
Gly	Ser	Pro	Thr	725	Met	Gly	Ser	Ser	Val	730	Met	Gly	Thr	Gln	Met	735	Asn
Val	Ile	Gly	Gln	740	Ser	Ala	Phe	Gly	Met	745	Gln	Gly	Asn	Pro	Phe	750	Phe
Asn	Pro	Gln	Asn	755	Phe	Ala	Gln	Pro	Pro	760	Thr	Thr	Met	Thr	Asn	765	Ser
Ser	Ser	Ala	Ser	770	Asn	Asp	Leu	Lys	Asp	775	Leu	Phe	Gly			780	
				785						790							

<210> 2

<211> 224

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 870615CD1

<400> 2

Met	Gly	Gly	Gly	Gly	Gly	Arg	Gly	Ser	Gly	Gly	Gly	Met	Asp	Gly			
1				5					10					15			
Trp	Asp	Gly	Ser	Ile	Arg	Glu	Val	Leu	Tyr	Arg	Gly	Asn	Ala	Asp			
				20					25					30			
Glu	Glu	Leu	Phe	Gln	Asp	Gln	Asp	Asp	Asp	Glu	Leu	Trp	Leu	Gly			
				35					40					45			
Asp	Ser	Gly	Ile	Thr	Asn	Trp	Asp	Asn	Val	Asp	Tyr	Met	Trp	Asp			
				50					55					60			
Glu	Glu	Glu	Glu	Glu	Glu	Glu	Asp	Gln	Asp	Tyr	Tyr	Leu	Gly	Gly			
				65					70					75			
Leu	Arg	Pro	Asp	Leu	Arg	Ile	Asp	Val	Tyr	Arg	Glu	Glu	Glu	Ile			
				80					85					90			
Leu	Glu	Ala	Tyr	Asp	Glu	Asp	Glu	Asp	Glu	Glu	Leu	Tyr	Pro	Asp			
				95					100					105			
Ile	His	Pro	Pro	Pro	Ser	Leu	Pro	Leu	Pro	Gly	Gln	Phe	Thr	Cys			
				110					115					120			
Pro	Gln	Cys	Arg	Lys	Ser	Phe	Thr	Arg	Arg	Ser	Phe	Arg	Pro	Asn			
				125					130					135			
Leu	Gln	Leu	Ala	Asn	Met	Val	Gln	Ile	Ile	Arg	Gln	Met	Cys	Pro			
				140					145					150			
Thr	Pro	Tyr	Arg	Gly	Asn	Arg	Ser	Asn	Asp	Gln	Gly	Met	Cys	Phe			
				155					160					165			
Lys	His	Gln	Glu	Ala	Leu	Lys	Leu	Phe	Cys	Glu	Val	Asp	Lys	Glu			
				170					175					180			
Ala	Ile	Cys	Val	Val	Cys	Arg	Glu	Ser	Arg	Ser	His	Lys	Gln	His			
				185					190					195			
Ser	Val	Val	Pro	Leu	Glu	Glu	Val	Val	Gln	Glu	Tyr	Gln	Lys	Ile			
				200					205					210			
Gly	Ser	Thr	Ser	Ser	Val	Glu	Leu	Ser	Glu	Ser	Val	Gly	Gln				

215

220

<210> 3
 <211> 374
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2762870CD1

<400> 3
 Met Ala Ala Pro Ala Leu Gly Leu Val Cys Gly Arg Cys Pro Glu
 1 5 10 15
 Leu Gly Leu Val Leu Leu Leu Leu Leu Ser Leu Leu Cys Gly
 20 25 30
 Ala Ala Gly Ser Gln Glu Ala Gly Thr Gly Ala Gly Ala Gly Ser
 35 40 45
 Leu Ala Gly Ser Cys Gly Cys Gly Thr Pro Gln Arg Pro Gly Ala
 50 55 60
 His Gly Ser Ser Ala Ala Ala His Arg Tyr Ser Arg Glu Ala Asn
 65 70 75
 Ala Pro Gly Pro Val Pro Gly Glu Arg Gln Leu Ala His Ser Lys
 80 85 90
 Met Val Pro Ile Pro Ala Gly Val Phe Thr Met Gly Thr Asp Asp
 95 100 105
 Pro Gln Ile Lys Gln Asp Gly Glu Ala Pro Ala Arg Arg Val Thr
 110 115 120
 Ile Asp Ala Phe Tyr Met Asp Ala Tyr Glu Val Ser Asn Thr Glu
 125 130 135
 Phe Glu Lys Phe Val Asn Ser Thr Gly Tyr Leu Thr Glu Ala Glu
 140 145 150
 Lys Phe Gly Asp Ser Phe Val Phe Glu Gly Met Leu Ser Glu Gln
 155 160 165
 Val Lys Thr Asn Ile Gln Gln Ala Val Ala Ala Ala Pro Trp Trp
 170 175 180
 Leu Pro Val Lys Gly Ala Asn Trp Arg His Pro Glu Gly Pro Asp
 185 190 195
 Ser Thr Ile Leu His Arg Pro Asp His Pro Val Leu His Val Ser
 200 205 210
 Trp Asn Asp Ala Val Ala Tyr Cys Thr Trp Ala Gly Lys Arg Leu
 215 220 225
 Pro Thr Glu Ala Glu Trp Glu Tyr Ser Cys Arg Gly Gly Leu His
 230 235 240
 Asn Arg Leu Phe Pro Trp Gly Asn Lys Leu Gln Pro Lys Gly Gln
 245 250 255
 His Tyr Ala Asn Ile Trp Gln Gly Glu Phe Pro Val Thr Asn Thr
 260 265 270
 Gly Glu Asp Gly Phe Gln Gly Thr Ala Pro Val Asp Ala Phe Pro
 275 280 285
 Pro Asn Gly Tyr Gly Leu Tyr Asn Ile Val Gly Asn Ala Trp Glu
 290 295 300
 Trp Thr Ser Asp Trp Trp Thr Val His His Ser Val Glu Glu Thr
 305 310 315
 Leu Asn Pro Lys Gly Pro Pro Ser Gly Lys Asp Arg Val Lys Lys
 320 325 330
 Gly Gly Ser Tyr Met Cys His Arg Ser Tyr Cys Tyr Arg Tyr Arg
 335 340 345
 Cys Ala Ala Arg Ser Gln Asn Thr Pro Asp Ser Ser Ala Ser Asn
 350 355 360
 Leu Gly Phe Arg Cys Ala Ala Asp Arg Leu Pro Thr Met Asp
 365 370

<210> 4
 <211> 565
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5507012CD1

<400> 4

Met	Ser	Gly	Gly	Ala	Ala	Glu	Lys	Gln	Ser	Ser	Thr	Pro	Gly	Ser
1				5					10					15
Leu	Phe	Leu	Ser	Pro	Pro	Ala	Pro	Ala	Pro	Lys	Asn	Gly	Ser	Ser
				20					25					30
Ser	Asp	Ser	Ser	Val	Gly	Glu	Lys	Leu	Gly	Ala	Ala	Ala	Ala	Asp
				35					40					45
Ala	Val	Thr	Gly	Arg	Thr	Glu	Glu	Tyr	Arg	Arg	Arg	Arg	His	Thr
				50					55					60
Met	Asp	Lys	Asp	Ser	Arg	Gly	Ala	Ala	Ala	Thr	Thr	Thr	Thr	Thr
				65					70					75
Glu	His	Arg	Phe	Phe	Arg	Arg	Ser	Val	Ile	Cys	Asp	Ser	Asn	Ala
				80					85					90
Thr	Ala	Leu	Glu	Leu	Pro	Gly	Leu	Pro	Leu	Ser	Leu	Pro	Gln	Pro
				95					100					105
Ser	Ile	Pro	Ala	Ala	Val	Pro	Gln	Ser	Ala	Pro	Pro	Glu	Pro	His
				110					115					120
Arg	Glu	Glu	Thr	Val	Thr	Ala	Thr	Ala	Thr	Ser	Gln	Val	Ala	Gln
				125					130					135
Gln	Pro	Pro	Ala	Ala	Ala	Ala	Pro	Gly	Glu	Gln	Ala	Val	Ala	Gly
				140					145					150
Pro	Ala	Pro	Ser	Thr	Val	Pro	Ser	Ser	Thr	Ser	Lys	Asp	Arg	Pro
				155					160					165
Val	Ser	Gln	Pro	Ser	Leu	Val	Gly	Ser	Lys	Glu	Glu	Pro	Pro	Pro
				170					175					180
Ala	Arg	Ser	Gly	Ser	Gly	Gly	Gly	Ser	Ala	Lys	Glu	Pro	Gln	Glu
				185					190					195
Glu	Arg	Ser	Gln	Gln	Gln	Asp	Asp	Ile	Glu	Glu	Leu	Glu	Thr	Lys
				200					205					210
Ala	Val	Gly	Met	Ser	Asn	Asp	Gly	Arg	Phe	Leu	Lys	Phe	Asp	Ile
				215					220					225
Glu	Ile	Gly	Arg	Gly	Ser	Phe	Lys	Thr	Val	Tyr	Lys	Gly	Leu	Asp
				230					235					240
Thr	Glu	Thr	Thr	Val	Glu	Val	Ala	Trp	Cys	Glu	Leu	Gln	Asp	Arg
				245					250					255
Lys	Leu	Thr	Lys	Ser	Glu	Arg	Gln	Arg	Phe	Lys	Glu	Glu	Ala	Glu
				260					265					270
Met	Leu	Lys	Gly	Leu	Gln	His	Pro	Asn	Ile	Val	Arg	Phe	Tyr	Asp
				275					280					285
Ser	Trp	Glu	Ser	Thr	Val	Lys	Gly	Lys	Lys	Cys	Ile	Val	Leu	Val
				290					295					300
Thr	Glu	Leu	Met	Thr	Ser	Gly	Thr	Leu	Lys	Thr	Tyr	Leu	Lys	Arg
				305					310					315
Phe	Lys	Val	Met	Lys	Ile	Lys	Val	Leu	Arg	Ser	Trp	Cys	Arg	Gln
				320					325					330
Ile	Leu	Lys	Gly	Leu	Gln	Phe	Leu	His	Thr	Arg	Thr	Pro	Pro	Ile
				335					340					345
Ile	His	Arg	Asp	Leu	Lys	Cys	Asp	Asn	Ile	Phe	Ile	Thr	Gly	Pro
				350					355					360
Thr	Gly	Ser	Val	Lys	Ile	Gly	Asp	Leu	Gly	Leu	Ala	Thr	Leu	Lys
				365					370					375
Arg	Ala	Ser	Phe	Ala	Lys	Ser	Val	Ile	Gly	Thr	Pro	Glu	Phe	Met
				380					385					390
Ala	Pro	Glu	Met	Tyr	Glu	Glu	Lys	Tyr	Asp	Glu	Ser	Val	Asp	Val

	395		400		405
Tyr Ala Phe Gly	Met Cys Met Leu Glu	Met Ala Thr Ser Glu	Tyr		
	410		415		420
Pro Tyr Ser Glu	Cys Gln Asn Ala Ala	Gln Ile Tyr Arg Arg	Val		
	425		430		435
Thr Ser Gly Val	Lys Pro Ala Ser Phe	Asp Lys Val Ala Ile	Pro		
	440		445		450
Glu Val Lys Glu	Ile Ile Glu Gly Cys	Ile Arg Gln Asn Lys	Asp		
	455		460		465
Glu Arg Tyr Ser	Ile Lys Asp Leu Leu	Asn His Ala Phe Phe	Gln		
	470		475		480
Glu Glu Thr Gly	Val Arg Val Glu Leu	Ala Glu Glu Asp Asp	Gly		
	485		490		495
Glu Lys Ile Ala	Ile Lys Leu Trp Leu	Arg Ile Glu Asp Ile	Lys		
	500		505		510
Lys Leu Lys Gly	Lys Tyr Lys Asp Asn	Glu Ala Ile Glu Phe	Ser		
	515		520		525
Phe Asp Leu Glu	Arg Asp Val Pro Glu	Asp Val Ala Gln Glu	Met		
	530		535		540
Val Glu Ser Gly	Tyr Val Cys Glu Gly	Asp His Lys Thr Met	Ala		
	545		550		555
Lys Ala Phe Lys	Asp Arg Val Ser Leu	Ile			
	560		565		

<210> 5

<211> 783

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6756529CD1

<400> 5

Met Val Ile Met Ser	Glu Phe Ser Ala Asp	Pro Ala Gly Gln Gly	
1	5	10	15
Gln Gly Gln Gln Lys	Pro Leu Arg Val Gly	Phe Tyr Asp Ile Glu	
	20	25	30
Arg Thr Leu Gly Lys	Gly Asn Phe Ala Val	Val Lys Leu Ala Arg	
	35	40	45
His Arg Val Thr Lys	Thr Gln Val Ala Ile	Lys Ile Ile Asp Lys	
	50	55	60
Thr Arg Leu Asp Ser	Ser Asn Leu Glu Lys	Ile Tyr Arg Glu Val	
	65	70	75
Gln Leu Met Lys Leu	Leu Asn His Pro His	Ile Ile Lys Leu Tyr	
	80	85	90
Gln Val Met Glu Thr	Lys Asp Met Leu Tyr	Ile Val Thr Glu Phe	
	95	100	105
Ala Lys Asn Gly Glu	Met Phe Asp Tyr Leu	Thr Ser Asn Gly His	
	110	115	120
Leu Ser Glu Asn Glu	Ala Arg Lys Lys Phe	Trp Gln Ile Leu Ser	
	125	130	135
Ala Val Glu Tyr Cys	His Asp His His Ile	Val His Arg Asp Leu	
	140	145	150
Lys Thr Glu Asn Leu	Leu Leu Asp Gly Asn	Met Asp Ile Lys Leu	
	155	160	165
Ala Asp Phe Gly Phe	Gly Asn Phe Tyr Lys	Ser Gly Glu Pro Leu	
	170	175	180
Ser Thr Trp Cys Gly	Ser Pro Pro Tyr Ala	Ala Pro Glu Val Phe	
	185	190	195
Glu Gly Lys Glu Tyr	Glu Gly Pro Gln Leu	Asp Ile Trp Ser Leu	
	200	205	210
Gly Val Val Leu Tyr	Val Leu Val Cys Gly	Ser Leu Pro Phe Asp	

	215		220		225
Gly Pro Asn Leu	Pro Thr Leu Arg Gln	Arg Val Leu Glu Gly	Arg		
	230		235		240
Phe Arg Ile Pro	Phe Phe Met Ser Gln	Asp Cys Glu Ser Leu	Ile		
	245		250		255
Arg Arg Met Leu	Val Val Asp Pro Ala	Arg Arg Ile Thr Ile	Ala		
	260		265		270
Gln Ile Arg Gln	His Arg Trp Met Arg	Ala Glu Pro Cys Leu	Pro		
	275		280		285
Gly Pro Ala Cys	Pro Ala Phe Ser Ala	His Ser Tyr Thr Ser	Asn		
	290		295		300
Leu Gly Asp Tyr	Asp Glu Gln Ala Leu	Gly Ile Met Gln Thr	Leu		
	305		310		315
Gly Val Asp Arg	Gln Arg Thr Val Glu	Ser Leu Gln Asn Ser	Ser		
	320		325		330
Tyr Asn His Phe	Ala Ala Ile Tyr Tyr	Leu Leu Leu Glu Arg	Leu		
	335		340		345
Lys Glu Tyr Arg	Asn Ala Gln Cys Ala	Arg Pro Gly Pro Ala	Arg		
	350		355		360
Gln Pro Arg Pro	Arg Ser Ser Asp Leu	Ser Gly Leu Glu Val	Pro		
	365		370		375
Gln Glu Gly Leu	Ser Thr Asp Pro Phe	Arg Pro Ala Leu Leu	Cys		
	380		385		390
Pro Gln Pro Gln	Thr Leu Val Gln Ser	Val Leu Gln Ala Glu	Met		
	395		400		405
Asp Cys Glu Leu	Gln Ser Ser Leu Gln	Trp Pro Leu Phe Phe	Pro		
	410		415		420
Val Asp Ala Ser	Cys Ser Gly Val Phe	Arg Pro Arg Pro Val	Ser		
	425		430		435
Pro Ser Ser Leu	Leu Asp Thr Ala Ile	Ser Glu Glu Ala Arg	Gln		
	440		445		450
Gly Pro Gly Leu	Glu Glu Glu Gln Asp	Thr Gln Glu Ser Leu	Pro		
	455		460		465
Ser Ser Thr Gly	Arg Arg His Thr Leu	Ala Glu Val Ser Thr	Arg		
	470		475		480
Leu Ser Pro Leu	Thr Ala Pro Cys Ile	Val Val Ser Pro Ser	Thr		
	485		490		495
Thr Ala Ser Pro	Ala Glu Gly Thr Ser	Ser Asp Ser Cys Leu	Thr		
	500		505		510
Phe Ser Ala Ser	Lys Ser Pro Ala Gly	Leu Ser Gly Thr Pro	Ala		
	515		520		525
Thr Gln Gly Leu	Leu Gly Ala Cys Ser	Pro Val Arg Leu Ala	Ser		
	530		535		540
Pro Phe Leu Gly	Ser Gln Ser Ala Thr	Pro Val Leu Gln Ala	Gln		
	545		550		555
Gly Gly Leu Gly	Gly Ala Val Leu Leu	Pro Val Ser Phe Gln	Glu		
	560		565		570
Gly Arg Arg Ala	Ser Asp Thr Ser Leu	Thr Gln Gly Leu Lys	Ala		
	575		580		585
Phe Arg Gln Gln	Leu Arg Lys Thr Thr	Arg Thr Lys Gly Phe	Leu		
	590		595		600
Gly Leu Asn Lys	Ile Lys Gly Leu Ala	Arg Gln Val Cys Gln	Val		
	605		610		615
Pro Ala Ser Arg	Ala Ser Arg Gly Gly	Leu Ser Pro Phe His	Ala		
	620		625		630
Pro Ala Gln Ser	Pro Gly Leu His Gly	Gly Ala Gly Gly Ser	Arg		
	635		640		645
Glu Gly Trp Ser	Leu Leu Glu Glu Val	Leu Glu Gln Gln Arg	Leu		
	650		655		660
Leu Gln Leu Gln	His His Pro Ala Ala	Ala Pro Gly Cys Ser	Gln		
	665		670		675
Ala Pro Gln Pro	Ala Pro Ala Pro Phe	Val Ile Ala Pro Cys	Asp		
	680		685		690

Gly	Pro	Gly	Ala	Ala	Pro	Leu	Pro	Ser	Thr	Leu	Leu	Thr	Ser	Gly	
				695					700					705	
Leu	Pro	Leu	Leu	Pro	Pro	Pro	Leu	Leu	Gln	Thr	Gly	Ala	Ser	Pro	
				710					715					720	
Val	Ala	Ser	Ala	Ala	Gln	Leu	Leu	Asp	Thr	His	Leu	His	Ile	Gly	
				725					730					735	
Thr	Gly	Pro	Thr	Ala	Leu	Pro	Ala	Val	Pro	Pro	Pro	Arg	Leu	Ala	
				740					745					750	
Arg	Leu	Ala	Pro	Gly	Cys	Glu	Pro	Leu	Gly	Leu	Leu	Gln	Gly	Asp	
				755					760					765	
Cys	Glu	Met	Glu	Asp	Leu	Met	Pro	Cys	Ser	Leu	Gly	Thr	Phe	Val	
				770					775					780	
Leu	Val	Gln													

<210> 6

<211> 798

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 387382CD1

<400> 6

Met	Ala	Ala	Ser	Leu	Pro	Gly	Pro	Gly	Ser	Arg	Leu	Phe	His	Thr	
1				5					10					15	
Tyr	Gly	Ala	Ala	Asp	Gly	Arg	Arg	Gln	Arg	Arg	Pro	Gly	Arg	Glu	
				20					25					30	
Ala	Ala	Gln	Trp	Phe	Pro	Pro	Gln	Asp	Arg	Arg	Arg	Phe	Phe	Asn	
				35					40					45	
Ser	Ser	Gly	Ser	Ser	Asp	Ala	Ser	Ile	Gly	Asp	Pro	Ser	Gln	Ser	
				50					55					60	
Asp	Asp	Pro	Asp	Asp	Pro	Asp	Asp	Pro	Asp	Phe	Pro	Gly	Ser	Pro	
				65					70					75	
Val	Arg	Arg	Arg	Arg	Arg	Cys	Pro	Gly	Gly	Arg	Val	Pro	Lys	Asp	
				80					85					90	
Arg	Pro	Ser	Leu	Thr	Val	Thr	Pro	Lys	Arg	Trp	Lys	Leu	Arg	Ala	
				95					100					105	
Arg	Pro	Ser	Leu	Thr	Val	Thr	Pro	Arg	Arg	Leu	Gly	Leu	Arg	Ala	
				110					115					120	
Arg	Pro	Pro	Gln	Lys	Cys	Ser	Thr	Pro	Cys	Gly	Pro	Leu	Arg	Leu	
				125					130					135	
Pro	Pro	Phe	Pro	Ser	Arg	Asp	Ser	Gly	Arg	Leu	Ser	Pro	Asp	Leu	
				140					145					150	
Ser	Val	Cys	Gly	Gln	Pro	Arg	Asp	Gly	Asp	Glu	Leu	Gly	Ile	Ser	
				155					160					165	
Ala	Ser	Leu	Phe	Ser	Ser	Leu	Ala	Ser	Pro	Cys	Pro	Gly	Ser	Pro	
				170					175					180	
Thr	Pro	Arg	Asp	Ser	Val	Ile	Ser	Ile	Gly	Thr	Ser	Ala	Cys	Leu	
				185					190					195	
Val	Ala	Ala	Ser	Ala	Val	Pro	Ser	Gly	Leu	His	Leu	Pro	Glu	Val	
				200					205					210	
Ser	Leu	Asp	Arg	Ala	Ser	Leu	Pro	Cys	Ser	Gln	Glu	Glu	Ala	Thr	
				215					220					225	
Gly	Gly	Ala	Lys	Asp	Thr	Arg	Met	Val	His	Gln	Thr	Arg	Ala	Ser	
				230					235					240	
Leu	Arg	Ser	Val	Leu	Phe	Gly	Leu	Met	Asn	Ser	Gly	Thr	Pro	Glu	
				245					250					255	
Asp	Ser	Glu	Phe	Arg	Ala	Asp	Gly	Lys	Asn	Met	Arg	Glu	Ser	Cys	
				260					265					270	
Cys	Lys	Arg	Lys	Leu	Val	Val	Gly	Asn	Gly	Pro	Glu	Gly	Pro	Gly	
				275					280					285	

Leu Ser Ser Thr	Gly Lys Arg Arg Ala Thr Gly Gln Asp Ser Cys	290	295	300
Gln Glu Arg Gly	Leu Gln Glu Ala Val Arg Arg Glu His Gln Glu	305	310	315
Ala Ser Val Pro	Lys Gly Arg Ile Val Pro Arg Gly Ile Asp Arg	320	325	330
Leu Glu Arg Thr	Arg Ser Ser Arg Lys Ser Lys His Gln Glu Ala	335	340	345
Thr Glu Thr Ser	Leu Leu His Ser His Arg Phe Lys Lys Gly Gln	350	355	360
Lys Leu Gly Lys	Asp Ser Phe Pro Thr Gln Asp Leu Thr Pro Leu	365	370	375
Gln Asn Ala Cys	Phe Trp Thr Lys Thr Arg Ala Ser Phe Ser Phe	380	385	390
His Lys Lys Lys	Ile Val Thr Asp Val Ser Glu Val Cys Ser Ile	395	400	405
Tyr Thr Thr Ala	Thr Ser Leu Ser Gly Ser Leu Leu Ser Glu Cys	410	415	420
Ser Asn Arg Pro	Val Met Asn Arg Thr Ser Gly Ala Pro Ser Ser	425	430	435
Trp His Ser Ser	Ser Met Tyr Leu Leu Ser Pro Leu Asn Thr Leu	440	445	450
Ser Ile Ser Asn	Lys Lys Ala Ser Asp Ala Glu Lys Val Tyr Gly	455	460	465
Glu Cys Ser Gln	Lys Gly Pro Val Pro Phe Ser His Cys Leu Pro	470	475	480
Thr Glu Lys Leu	Gln Arg Cys Glu Lys Ile Gly Glu Gly Val Phe	485	490	495
Gly Glu Val Phe	Gln Thr Ile Ala Asp His Thr Pro Val Ala Ile	500	505	510
Lys Ile Ile Ala	Ile Glu Gly Pro Asp Leu Val Asn Gly Ser His	515	520	525
Gln Lys Thr Phe	Glu Glu Ile Leu Pro Glu Ile Ile Ile Ser Lys	530	535	540
Glu Leu Ser Leu	Leu Ser Gly Glu Val Cys Asn Arg Thr Glu Gly	545	550	555
Phe Ile Gly Leu	Asn Ser Val His Cys Val Gln Gly Ser Tyr Pro	560	565	570
Pro Leu Leu Leu	Lys Ala Trp Asp His Tyr Asn Ser Thr Lys Gly	575	580	585
Ser Ala Asn Asp	Arg Pro Asp Phe Phe Lys Asp Asp Gln Leu Phe	590	595	600
Ile Val Leu Glu	Phe Glu Phe Gly Gly Ile Asp Leu Glu Gln Met	605	610	615
Arg Thr Lys Leu	Ser Ser Leu Ala Thr Ala Lys Ser Ile Leu His	620	625	630
Gln Leu Thr Ala	Ser Leu Ala Val Ala Glu Ala Ser Leu Arg Phe	635	640	645
Glu His Arg Asp	Leu His Trp Gly Asn Val Leu Leu Lys Lys Thr	650	655	660
Ser Leu Lys Lys	Leu His Tyr Thr Leu Asn Gly Lys Ser Ser Thr	665	670	675
Ile Pro Ser Cys	Gly Leu Gln Val Ser Ile Ile Asp Tyr Thr Leu	680	685	690
Ser Arg Leu Glu	Arg Asp Gly Ile Val Val Phe Cys Asp Val Ser	695	700	705
Met Asp Glu Asp	Leu Phe Thr Gly Asp Gly Asp Tyr Gln Phe Asp	710	715	720
Ile Tyr Arg Leu	Met Lys Lys Glu Asn Asn Asn Arg Trp Gly Glu	725	730	735
Tyr His Pro Tyr	Ser Asn Val Leu Trp Leu His Tyr Leu Thr Asp	740	745	750
Lys Met Leu Lys	Gln Met Thr Phe Lys Thr Lys Cys Asn Thr Pro			

	755		760		765
Ala Met Lys Gln	Ile Lys Arg Lys Ile	Gln Glu Phe His Arg	Thr		
	770		775		780
Met Leu Asn Phe	Ser Ser Ala Thr Asp	Leu Leu Cys Gln His	Ser		
	785		790		795
Leu Phe Lys					

<210> 7
 <211> 632
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5850786CD1

<400> 7

Met Phe Gly Lys	Lys Lys Lys Lys Ile	Glu Ile Ser Gly Pro Ser	
1	5	10	15
Asn Phe Glu His	Arg Val His Thr Gly	Phe Asp Pro Gln Glu Gln	
	20	25	30
Lys Phe Thr Gly	Leu Pro Gln Gln Trp	His Ser Leu Leu Ala Asp	
	35	40	45
Thr Ala Asn Arg	Pro Lys Pro Met Val	Asp Pro Ser Cys Ile Thr	
	50	55	60
Pro Ile Gln Leu	Ala Pro Met Lys Thr	Ile Val Arg Gly Asn Lys	
	65	70	75
Pro Cys Lys Glu	Thr Ser Ile Asn Gly	Leu Leu Glu Asp Phe Asp	
	80	85	90
Asn Ile Ser Val	Thr Arg Ser Asn Ser	Leu Arg Lys Glu Ser Pro	
	95	100	105
Pro Thr Pro Asp	Gln Gly Ala Ser Ser	His Gly Pro Gly His Ala	
	110	115	120
Glu Glu Asn Gly	Phe Ile Thr Phe Ser	Gln Tyr Ser Ser Glu Ser	
	125	130	135
Asp Thr Thr Ala	Asp Tyr Thr Thr Glu	Lys Tyr Arg Glu Lys Ser	
	140	145	150
Leu Tyr Gly Asp	Asp Leu Asp Pro Tyr	Tyr Arg Gly Ser His Ala	
	155	160	165
Ala Lys Gln Asn	Gly His Val Met Lys	Met Lys His Gly Glu Ala	
	170	175	180
Tyr Tyr Ser Glu	Val Lys Pro Leu Lys	Ser Asp Phe Ala Arg Phe	
	185	190	195
Ser Ala Asp Tyr	His Ser His Leu Asp	Ser Leu Ser Lys Pro Ser	
	200	205	210
Glu Tyr Ser Asp	Leu Lys Trp Glu Tyr	Gln Arg Ala Ser Ser Ser	
	215	220	225
Ser Pro Leu Asp	Tyr Ser Phe Gln Phe	Thr Pro Ser Arg Thr Ala	
	230	235	240
Gly Thr Ser Gly	Cys Ser Lys Glu Ser	Leu Ala Tyr Ser Glu Ser	
	245	250	255
Glu Trp Gly Pro	Ser Leu Asp Asp Tyr	Asp Arg Arg Pro Lys Ser	
	260	265	270
Ser Tyr Leu Asn	Gln Thr Ser Pro Gln	Pro Thr Met Arg Gln Arg	
	275	280	285
Ser Arg Ser Gly	Ser Gly Leu Gln Glu	Pro Met Met Pro Phe Gly	
	290	295	300
Ala Ser Ala Phe	Lys Thr His Pro Gln	Gly His Ser Tyr Asn Ser	
	305	310	315
Tyr Thr Tyr Pro	Arg Leu Ser Glu Pro	Thr Met Cys Ile Pro Lys	
	320	325	330
Val Asp Tyr Asp	Arg Ala Gln Met Val	Leu Ser Pro Pro Leu Ser	

	335		340		345
Gly Ser Asp Thr	Tyr Pro Arg Gly Pro	Ala Lys Leu Pro Gln Ser			
	350		355		360
Gln Ser Lys Ser	Gly Tyr Ser Ser Ser	Ser His Gln Tyr Pro Ser			
	365		370		375
Gly Tyr His Lys	Ala Thr Leu Tyr His	His Pro Ser Leu Gln Ser			
	380		385		390
Ser Ser Gln Tyr	Ile Ser Thr Ala Ser	Tyr Leu Ser Ser Leu Ser			
	395		400		405
Leu Ser Ser Ser	Thr Tyr Pro Pro Pro	Ser Trp Gly Ser Ser Ser			
	410		415		420
Asp Gln Gln Pro	Ser Arg Val Ser His	Glu Gln Phe Arg Ala Ala			
	425		430		435
Leu Gln Leu Val	Val Ser Pro Gly Asp	Pro Arg Glu Tyr Leu Ala			
	440		445		450
Asn Phe Ile Lys	Ile Gly Glu Gly Ser	Thr Gly Ile Val Cys Ile			
	455		460		465
Ala Thr Glu Lys	His Thr Gly Lys Gln	Val Ala Val Lys Lys Met			
	470		475		480
Asp Leu Arg Lys	Gln Gln Arg Arg Glu	Leu Leu Phe Asn Glu Val			
	485		490		495
Val Ile Met Arg	Asp Tyr His His Asp	Asn Val Val Asp Met Tyr			
	500		505		510
Ser Ser Tyr Leu	Val Gly Asp Glu Leu	Trp Val Val Met Glu Phe			
	515		520		525
Leu Glu Gly Gly	Ala Leu Thr Asp Ile	Val Thr His Thr Arg Met			
	530		535		540
Asn Glu Glu Gln	Ile Ala Thr Val Cys	Leu Ser Val Leu Arg Ala			
	545		550		555
Leu Ser Tyr Leu	His Asn Gln Gly Val	Ile His Arg Asp Ile Lys			
	560		565		570
Ser Asp Ser Ile	Leu Leu Thr Ser Asp	Gly Arg Val Ser Ser Val			
	575		580		585
Leu Arg Gly Phe	Leu Asp Leu Met Leu	Val Arg Glu Pro Ser Gln			
	590		595		600
Arg Ala Thr Ala	Gln Glu Leu Leu Gly	His Pro Phe Leu Lys Leu			
	605		610		615
Ala Gly Pro Pro	Ser Cys Ile Val Pro	Leu Met Arg Gln Tyr Arg			
	620		625		630
His His					

<210> 8

<211> 350

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7182343CD1

<400> 8

Met Arg Arg Arg Val	Ile Ala Arg Pro Val Gly Ser Ser Val Arg
1	5 10 15
Leu Lys Cys Val Ala	Ser Gly His Pro Arg Pro Asp Ile Thr Trp
	20 25 30
Met Lys Asp Asp Gln	Ala Leu Thr Arg Pro Glu Ala Ala Glu Pro
	35 40 45
Arg Lys Lys Lys Trp	Thr Leu Ser Leu Lys Asn Leu Arg Pro Glu
	50 55 60
Asp Ser Gly Lys Tyr	Thr Cys Arg Val Ser Asn Arg Ala Gly Ala
	65 70 75
Ile Asn Ala Thr Tyr	Lys Val Asp Val Ile Gln Arg Thr Arg Ser

	80		85		90
Lys Pro Val Leu Thr	Gly Thr His Pro Val Asn Thr Thr Val Asp				
	95		100		105
Phe Gly Gly Thr Thr	Ser Phe Gln Cys Lys Val Arg Ser Asp Val				
	110		115		120
Lys Pro Val Ile Gln	Trp Leu Lys Arg Val Glu Tyr Gly Ala Glu				
	125		130		135
Gly Arg His Asn Ser	Thr Ile Asp Val Gly Gly Gln Lys Phe Val				
	140		145		150
Val Leu Pro Thr Gly	Asp Val Trp Ser Arg Pro Asp Gly Ser Tyr				
	155		160		165
Leu Asn Lys Leu Leu	Ile Thr Arg Ala Arg Gln Asp Asp Ala Glu				
	170		175		180
Met Tyr Ile Cys Leu	Gly Ala Asn Thr Met Gly Tyr Ser Phe Arg				
	185		190		195
Ser Ala Phe Leu Thr	Val Leu Pro Asp Pro Lys Pro Pro Gly Pro				
	200		205		210
Pro Val Ala Ser Ser	Ser Ser Ala Thr Ser Leu Pro Trp Pro Val				
	215		220		225
Val Ile Gly Ile Pro	Ala Gly Ala Val Phe Ile Leu Gly Thr Leu				
	230		235		240
Leu Leu Trp Leu Cys	Gln Ala Gln Lys Lys Pro Cys Thr Pro Ala				
	245		250		255
Pro Ala Pro Pro Leu	Pro Gly His Arg Pro Pro Gly Thr Ala Arg				
	260		265		270
Asp Arg Ser Gly Asp	Lys Asp Leu Pro Ser Leu Ala Ala Leu Ser				
	275		280		285
Ala Gly Pro Gly Val	Gly Leu Cys Glu Glu His Gly Ser Pro Ala				
	290		295		300
Ala Pro Gln His Leu	Gly Pro Gly Pro Val Ala Gly Pro Lys				
	305		310		315
Leu Tyr Pro Lys Leu	Tyr Thr Asp Ile His Thr His Thr His Thr				
	320		325		330
His Ser His Thr His	Ser His Val Glu Gly Lys Val His Gln His				
	335		340		345
Ile His Tyr Gln Cys					
	350				

<210> 9

<211> 571

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7264345CD1

<400> 9

Met Asp Arg Ser Lys	Arg Asn Ser Ile Ala Gly Phe Pro Pro Arg				
1	5		10		15
Val Glu Arg Leu Glu	Glu Phe Glu Gly Gly Gly Gly Gly Glu Gly				
	20		25		30
Asn Val Ser Gln Val	Gly Arg Val Trp Pro Ser Ser Tyr Arg Ala				
	35		40		45
Leu Ile Ser Ala Phe	Ser Arg Leu Thr Arg Leu Asp Asp Phe Thr				
	50		55		60
Cys Glu Lys Ile Gly	Ser Gly Phe Phe Ser Glu Val Phe Lys Val				
	65		70		75
Arg His Arg Ala Ser	Gly Gln Val Met Ala Leu Lys Met Asn Thr				
	80		85		90
Leu Ser Ser Asn Arg	Ala Asn Met Leu Lys Glu Val Gln Leu Met				
	95		100		105
Asn Arg Leu Ser His	Pro Asn Ile Leu Arg Phe Met Gly Val Cys				

	110		115		120
Val His Gln Gly	Gln Leu His Ala Leu	Thr Glu Tyr Ile Asn	Ser		
	125		130		135
Gly Asn Leu Glu	Gln Leu Leu Asp Ser	Asn Leu His Leu Pro	Trp		
	140		145		150
Thr Val Arg Val	Lys Leu Ala Tyr Asp	Ile Ala Val Gly Leu	Ser		
	155		160		165
Tyr Leu His Phe	Lys Gly Ile Phe His	Arg Asp Leu Thr Ser	Lys		
	170		175		180
Asn Cys Leu Ile	Lys Arg Asp Glu Asn	Gly Tyr Ser Ala Val	Val		
	185		190		195
Ala Asp Phe Gly	Leu Ala Glu Lys Ile	Pro Asp Val Ser Met	Gly		
	200		205		210
Ser Glu Lys Leu	Ala Val Val Gly Ser	Pro Phe Trp Met Ala	Pro		
	215		220		225
Glu Val Leu Arg	Asp Glu Pro Tyr Asn	Glu Lys Ala Asp Val	Phe		
	230		235		240
Ser Tyr Gly Ile	Ile Leu Cys Glu Ile	Ile Ala Arg Ile Gln	Ala		
	245		250		255
Asp Pro Asp Tyr	Leu Pro Arg Thr Glu	Asn Phe Gly Leu Asp	Tyr		
	260		265		270
Asp Ala Phe Gln	His Met Val Gly Asp	Cys Pro Pro Asp Phe	Leu		
	275		280		285
Gln Leu Thr Phe	Asn Cys Cys Asn Met	Asp Pro Lys Leu Arg	Pro		
	290		295		300
Ser Phe Val Glu	Ile Gly Lys Thr Leu	Glu Glu Ile Leu Ser	Arg		
	305		310		315
Leu Gln Glu Glu	Glu Gln Glu Arg Asp	Arg Lys Leu Gln Pro	Thr		
	320		325		330
Ala Arg Gly Leu	Leu Glu Lys Ala Pro	Gly Val Lys Arg Leu	Ser		
	335		340		345
Ser Leu Asp Asp	Lys Ile Pro His Lys	Ser Pro Cys Pro Arg	Arg		
	350		355		360
Thr Ile Trp Leu	Ser Arg Ser Gln Ser	Asp Ile Phe Ser Arg	Lys		
	365		370		375
Pro Pro Arg Thr	Val Ser Val Leu Asp	Pro Tyr Tyr Arg Pro	Arg		
	380		385		390
Asp Gly Ala Ala	Arg Thr Pro Lys Val	Asn Pro Phe Ser Ala	Arg		
	395		400		405
Gln Asp Leu Met	Gly Gly Lys Ile Lys	Phe Phe Asp Leu Pro	Ser		
	410		415		420
Lys Ser Val Ile	Ser Leu Val Phe Asp	Leu Asp Ala Pro Gly	Pro		
	425		430		435
Gly Thr Met Pro	Leu Ala Asp Trp Gln	Glu Pro Leu Ala Pro	Pro		
	440		445		450
Ile Arg Arg Trp	Arg Ser Leu Pro Gly	Ser Pro Glu Phe Leu	His		
	455		460		465
Gln Glu Ala Cys	Pro Phe Val Gly Arg	Glu Glu Ser Leu Ser	Asp		
	470		475		480
Gly Pro Pro Pro	Arg Leu Ser Ser Leu	Lys Tyr Arg Val Lys	Glu		
	485		490		495
Ile Pro Pro Phe	Arg Ala Ser Ala Leu	Pro Ala Ala Gln Ala	His		
	500		505		510
Glu Ala Met Asp	Cys Ser Ile Leu Gln	Glu Glu Asn Gly Phe	Gly		
	515		520		525
Ser Arg Pro Gln	Gly Thr Ser Pro Cys	Pro Ala Gly Ala Ser	Glu		
	530		535		540
Glu Met Glu Val	Glu Glu Arg Pro Ala	Gly Ser Thr Pro Ala	Thr		
	545		550		555
Phe Ser Thr Ser	Gly Ile Gly Leu Gln	Thr Gln Gly Lys Gln	Asp		
	560		565		570
Gly					

<210> 10
 <211> 323
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472328CD1

<400> 10

Met	Arg	Ala	Thr	Pro	Leu	Ala	Ala	Ser	Ala	Gly	Ser	Leu	Ser	Arg
1				5					10					15
Lys	Lys	Arg	Leu	Glu	Leu	Asp	Asp	Asn	Leu	Asp	Thr	Glu	Arg	Pro
				20					25					30
Val	Gln	Lys	Arg	Ala	Arg	Ser	Gly	Pro	Gln	Pro	Arg	Leu	Pro	Pro
				35					40					45
Cys	Leu	Leu	Pro	Leu	Ser	Pro	Pro	Thr	Ala	Pro	Asp	Arg	Ala	Thr
				50					55					60
Ala	Val	Ala	Thr	Ala	Ser	Arg	Leu	Gly	Pro	Tyr	Val	Leu	Leu	Glu
				65					70					75
Pro	Glu	Glu	Gly	Gly	Arg	Ala	Tyr	Gln	Ala	Leu	His	Cys	Pro	Thr
				80					85					90
Gly	Thr	Glu	Tyr	Thr	Cys	Lys	Val	Tyr	Pro	Val	Gln	Glu	Ala	Leu
				95					100					105
Ala	Val	Leu	Glu	Pro	Tyr	Ala	Arg	Leu	Pro	Pro	Asp	Lys	His	Val
				110					115					120
Ala	Trp	Pro	Thr	Glu	Gly	Leu	Ala	Gly	Thr	Gln	Leu	Leu	Tyr	Ala
				125					130					135
Phe	Phe	Thr	Trp	Thr	His	Gly	Asp	Met	His	Arg	Leu	Ile	Gly	His
				140					145					150
Thr	Pro	Cys	Ala	His	Cys	Asp	Gln	Thr	Arg	Lys	Lys	Leu	Val	Leu
				155					160					165
Glu	Asn	Leu	Glu	Asp	Ser	Cys	Val	Leu	Thr	Gly	Pro	Asp	Asp	Ser
				170					175					180
Leu	Trp	Asp	Lys	His	Ala	Cys	Pro	Ala	Tyr	Val	Gly	Pro	Glu	Ile
				185					190					195
Leu	Ser	Ser	Arg	Ala	Ser	Tyr	Ser	Gly	Lys	Ala	Ala	Asn	Val	Trp
				200					205					210
Ser	Leu	Gly	Val	Ala	Leu	Phe	Thr	Met	Leu	Ala	Gly	His	Tyr	Pro
				215					220					225
Phe	Gln	Asp	Ser	Glu	Pro	Val	Leu	Leu	Phe	Gly	Lys	Ile	Arg	Arg
				230					235					240
Gly	Ala	Tyr	Ala	Leu	Pro	Ala	Gly	Leu	Ser	Ala	Pro	Ala	Arg	Cys
				245					250					255
Leu	Val	Arg	Cys	Leu	Leu	Arg	Arg	Glu	Pro	Ala	Glu	Arg	Leu	Thr
				260					265					270
Ala	Thr	Gly	Ile	Leu	Leu	His	Pro	Trp	Leu	Arg	Gln	Asp	Pro	Met
				275					280					285
Pro	Leu	Ala	Pro	Thr	Arg	Ser	His	Leu	Trp	Glu	Ala	Ala	Gln	Val
				290					295					300
Val	Pro	Asp	Gly	Leu	Gly	Leu	Asp	Glu	Ala	Arg	Glu	Glu	Glu	Gly
				305					310					315
Asp	Arg	Glu	Val	Val	Leu	Tyr	Gly							
				320										

<210> 11
 <211> 471
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1471412CD1

<400> 11
Met Glu Asn Leu Lys His Ile Ile Thr Leu Gly Gln Val Ile His
1 5 10 15
Lys Arg Cys Glu Glu Met Lys Tyr Cys Lys Lys Gln Cys Arg Arg
20 25 30
Leu Gly His Arg Val Leu Gly Leu Ile Lys Pro Leu Glu Met Leu
35 40 45
Gln Asp Gln Gly Lys Arg Ser Val Pro Ser Glu Lys Leu Thr Thr
50 55 60
Ala Met Asn Arg Phe Lys Ala Ala Leu Glu Glu Ala Asn Gly Glu
65 70 75
Ile Glu Lys Phe Ser Asn Arg Ser Asn Ile Cys Arg Phe Leu Thr
80 85 90
Ala Ser Gln Asp Lys Ile Leu Phe Lys Asp Val Asn Arg Lys Leu
95 100 105
Ser Asp Val Trp Lys Glu Leu Ser Leu Leu Leu Gln Val Glu Gln
110 115 120
Arg Met Pro Val Ser Pro Ile Ser Gln Gly Ala Ser Trp Ala Gln
125 130 135
Glu Asp Gln Gln Asp Ala Asp Glu Asp Arg Arg Ala Phe Gln Met
140 145 150
Leu Arg Arg Asp Asn Glu Lys Ile Glu Ala Ser Leu Arg Arg Leu
155 160 165
Glu Ile Asn Met Lys Glu Ile Lys Glu Thr Leu Arg Gln Tyr Leu
170 175 180
Pro Pro Lys Cys Met Gln Glu Ile Pro Gln Glu Gln Ile Lys Glu
185 190 195
Ile Lys Lys Glu Gln Leu Ser Gly Ser Pro Trp Ile Leu Leu Arg
200 205 210
Glu Asn Glu Val Ser Thr Leu Tyr Lys Gly Glu Tyr His Arg Ala
215 220 225
Pro Val Ala Ile Lys Val Phe Lys Lys Leu Gln Ala Gly Ser Ile
230 235 240
Ala Ile Val Arg Gln Thr Phe Asn Lys Glu Ile Lys Thr Met Lys
245 250 255
Lys Phe Glu Ser Pro Asn Ile Leu Arg Ile Phe Gly Ile Cys Ile
260 265 270
Asp Glu Thr Val Thr Pro Pro Gln Phe Ser Ile Val Met Glu Tyr
275 280 285
Cys Glu Leu Gly Thr Leu Arg Glu Leu Leu Asp Arg Glu Lys Asp
290 295 300
Leu Thr Leu Gly Lys Arg Met Val Leu Val Leu Gly Ala Ala Arg
305 310 315
Gly Leu Tyr Arg Leu His His Ser Glu Ala Pro Glu Leu His Gly
320 325 330
Lys Ile Arg Ser Ser Asn Phe Leu Val Thr Gln Gly Tyr Gln Val
335 340 345
Lys Leu Ala Gly Phe Glu Leu Arg Lys Thr Gln Thr Ser Met Ser
350 355 360
Leu Gly Thr Thr Arg Glu Lys Thr Asp Arg Val Lys Ser Thr Ala
365 370 375
Tyr Leu Ser Pro Gln Glu Leu Glu Asp Val Phe Tyr Gln Tyr Asp
380 385 390
Val Lys Ser Glu Ile Tyr Ser Phe Gly Ile Val Leu Trp Glu Ile
395 400 405
Ala Thr Gly Asp Ile Pro Phe Gln Gly Cys Asn Ser Glu Lys Ile
410 415 420
Arg Lys Leu Val Ala Val Lys Arg Gln Gln Glu Pro Leu Gly Glu
425 430 435
Asp Cys Pro Ser Glu Leu Arg Glu Ile Ile Asp Glu Cys Arg Ala
440 445 450
His Asp Pro Ser Val Arg Pro Ser Val Asp Glu Ile Leu Lys Lys
455 460 465

Leu Ser Thr Phe Ser Lys
470

<210> 12
<211> 4335
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4912053CB1

<400> 12
atgaaagagc acttcttcag tgcctctttc agtgatacaa agttaaaacc aggtactgtt 60
tctgaaggat tgtcattctt gcatagcagt gtgaaaatgg tgcattggaaa tatcactcct 120
gaaaatataa ttttgaataa aagtggagcc tggaaaataa tgggttttga tttttgtgta 180
tcatcaacca atccttctga acaagagcct aaatttcctt gtaaagaatg ggacccaaat 240
ttaccttcat tgtgtcttcc aaatcctgaa tatttggctc ctgaatacat actttctgtg 300
agctgtgaaa cagccagtga tatgtattct ttaggaactg ttatgtatgc tgtatttaaat 360
aaagggaaac ctatatattga agtcaacaag caagatatctt acaagagttt cagtaggcag 420
ttggatcagt tgagtcgttt aggatctagt tcacttacaa atataacctga ggaagttcgt 480
gaacatgtaa agctactgtt aaatgtaact ccgactgtaa gaccagatgc agatcaaagt 540
acaaagattc ccttctttga tgaatgttgt gcagtaaacac tgcaatattt tgatacctta 600
ttccaaagag ataactttca gaaatcacag tttttcaaag gactgccaaa gggtctacca 660
aaactgcccc agcgtgtcat tgtgcagaga attttgcctt gtttgacttc agaatttgta 720
aaccctgaca tggtagcttt tgttttgcct aatgttctac ttattgctga ggaatgcacc 780
aaagaagaat atgtcaaatt aattcttctt gaacttggcc ctgtgtttta gcagcaggag 840
ccaatccagg ctagcaacat gattttgtta attttctac aaaaaatgga tttgctacta 900
accaaaccct ctctgatga gataaagaac agtgttctac ccatgggtta cagagcacta 960
gaagctcctt ccattcagat ccaggagctc tgtctaaaca tcattccaac ctttgcaaat 1020
cttatagact acccatccat gaaaaacgct ttgataccaa gaattaaaaa tgcttgccta 1080
caaactcctt cccttgcggt tctgtgtaaat tcattagtgt gcttaggaaa gattttggaa 1140
tacttggata agtggtttgt acttgatgat atcctaccct tcttacaaca aattccatcc 1200
aaggaacctg cggctctcat gggaatttta ggtatttaca aatgtacttt tactcataag 1260
aagttgggaa tcaccaaaga gcagctggcc ggaaaagtgt tgcctcatct tattccctg 1320
agtattgaaa acaatcttaa tcttaatcag ttcaattctt tcatttccgt cataaagaa 1380
atgcttaata gattggagtc tgaacataag actaaactgg agcaacttca tataatgcaa 1440
gaacagcaga aatcttttga tataggaaat caaatgaatg tttctgagga gatgaaagtt 1500
acaaatattg ggaatcagca aattgacaaa gtttttaaca acattggagc agacctctg 1560
actggcagtg agtccgaaaa taaagaggac gggttacaga ataaacataa aagagcatca 1620
cttactcttg aagaaaaaca aaaattagca aaagaacaag agcaggcaca gaagctgaaa 1680
agccagcagc ctcttaaacc ccaagtgcac acacctgttg ctactgttaa acagactaag 1740
gacttgacag acacactgat ggataatatg tcatccttga ccagccttct tggtagtacc 1800
cctaaatctt ctgcttcaag tactttcact tctgttctct ccatgggcat tggtagatg 1860
ttttctacac caactgataa tacaaagaga aatttgacaa atggcctaaa tgccaatatg 1920
ggctttcaga cttcaggatt caacatgccc gttaatacaa accagaactt ctacagtagt 1980
ccaagcacag ttggagtgcac caagatgact ctgggaacac ctcccacttt gccaaacttc 2040
aatgctttga gtgttctctc tgcctgggca aagcagacc aacaaagacc cacagatatg 2100
tctgccctta ataactctt tggccctcag aaacccaaag ttagcatgaa ccagttatca 2160
caacagaaac caaatcagtg gcttaatcag tttgtacctc ctcaaggttc tccaactatg 2220
ggcagttcag taatggggac acagatgaac gtgataggac aatctgcttt tggtagtcag 2280
ggtaatcctt tctttaaccc acagaacttt gcacagccac caactactat gaccaatagc 2340
agttcagcta gcaatgattt aaaagatctt tttgggtgag gtgtcttact tctattttga 2400
aggattatct cagtttcaat catgggtgag ctgatttaca tctttatata gttggcttgg 2460
aggaagtact tctatgggaa agtgaacagt tctgtgacag gaaacatctc tgtccatgcc 2520
agcatagtag ttgtatggac ttctaaccag ttgagttttt taaagcattg aggatttttt 2580
cctcttacca actcctcttc aggtttttta agacccagcc cttcccaatc tcaaagagaa 2640
aaaggaaaact gagtattctt gaataacata actttttaat caaatgttta ttttggcttg 2700
tggatcttgg tgttatttaa aaaattgagg tgatgggtcat tgcaagctca tctatttaagt 2760
actatatggt acacagtcta tgagtcatta gtcttcattt taatatgtaa aaaatcttga 2820
tgctgtattg atttgtttgc atttaagatg acagtgaaga aatgataagc ataaagagaa 2880
gtatcaggtt atttgctttt tccaaacttt tcagatgaac tattgttttag tacagagact 2940
gagcaaatac tacaaaattc aacttaacct tcatttcatt ggtttaaatg cgttattaac 3000

```

catcttaagt gcaaactaat cattgtaaat tatatttttag catggtctgc ctcaaatagt 3060
aatgtatttt tctgcattca cttggatata tttagaatca cttttttcct cctgtatcaa 3120
ggaagaggta tgtgctgatt tgtttggata tttgacaagg cactctgatg tgacttccct 3180
gactactacc ttcataatttc atttcaaatt caaacttctg aggttgcagc atatatgaat 3240
tgcatttttca aaagaagatt tgtaagaatt aaactatatt tatgagtaaa ctttttgaggt 3300
ttctgctgta ttgtttcaaa tgtaataaac tttacttctg taaaaattga gcagttgtat 3360
cttctgacca ccaacagatt ttcagcttgc catgatagtc tgacctcatt aattactgct 3420
actgaagttc aatttttttc taggaatttt aggaaccttt tgttttaaata ttttaatttc 3480
tattagccat ttttaggaag gaaagaatca attctcttaa caggaaacat gctttatttt 3540
tcaaaacctt tctctgatat ttttctttta tttgctgatt attcaaccac agagccttat 3600
gctataaatg tcatttgtat tttaaaaaat aatattccac tcataaaact ttaaaacccat 3660
ctttcaacga actatatatg tattatagtt gctgccatag agttgatggt ttttaattat 3720
ctggaaccag caatcattta aaataaacca tattaagttt agtatgctgg tattgtttat 3780
tcattttata tgaatattca ttgaaaatat atacacaata tatgtaatac acagcacttg 3840
attacaaaat gtaattttaat tatattattg ctggcagcat tcagttaaga ggggtacttta 3900
aaaaatagaa gtcagctttc acatctgatt tctgtatggg ctgtacttgg ttaacttgat 3960
tttagaaaaa ggactaacag aattgctaaa gaaatgcac caataaatga aaaacagtag 4020
gaagatcaaa tgtttttgtc aaatatattc acaacttgac cagattagct gtccctgtttg 4080
taatgcaata ttaatatgtc ttttgggaaa aagcctacat atggaataaa ataagtattg 4140
aagaattttt ctttgtaaca atttagtagt cactgtttat tgagaaattg ttttttattt 4200
tgtaaaataa catgatgtaa gtgttgacct cttaaacaga gagagcgctt aatatcaccg 4260
catatgctc ttgacctcct atatgtgaat atgacacatg tgcaaaatac agtgtgtgaa 4320
atctgtgcac acgct
4335

```

<210> 13

<211> 1829

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 870615CB1

<400> 13

```

gcggctgcat ctgaggcgga cgccgcagtg tagggcacac cctgagggta gcgagagacg 60
tgacaggacc gagcagctgg gggctgcagc ctgctctgtc cccaccgatc ccagagagag 120
gctgtgagtc tggatctggg cgttcgcacc ctgagagagg ggggtcaaagc tcccctgcgg 180
ccccgaggaa gaagagcaag gttgaggaca gcctcgggtc accagagtag tttggaggca 240
ggcctgcagg cgcgtccccg ctectcagct ccaagctgac gtatctacac ctgccggcgg 300
gcattaagat ggctggttat gccactactc agacccccat gcagacctt caggaggaag 360
cgggtgtgtgc catctgcttg gattacttca aggacccccg gtccatcagc tgtgggcaca 420
acttctgccg aggggtgtgtg acccagctgt ggagtaagga ggacgaggag gccagaacg 480
aggaggaaga tgaatgggag gaggaggagg acgaggaagc ggtgggggca tggatggatg 540
ggacggctcc attcgagagg tgttgatcgc ggggaatgct gacgaagagt tgttccaaga 600
ccaagatgac gatgaactct ggctcgggtg cagtgggtata actaattggg acaacgtaga 660
ctatatgtgg gacgaggagg aagaagaaga ggaagatcag gactattacc taggaggctt 720
gagacctgac ctgagaattg atgtctaccg agaagaagaa atactggaag catacgatga 780
ggacgaagat gaagagctgt atcctgacat ccacccgcct cttccttgc cccttcagg 840
gcagttcacc tgccccagc gccgaaagag ctttacacgt cgcagcttc gtcccaactt 900
gcagctggcc aacatgggtc agataattcg ccagatgtgc cccactcctt atcggggaaa 960
ccggagtaat gatcagggca tgtgctttta acaccaggaa gccctgaaac tcttctgtga 1020
ggtggacaaa gaggccatct gtgtggtgtg ccgagaatcc aggagccaca aacagcacag 1080
cgtggtgcca ttggaggagg tgggtgcagg gtaccagaag atagggtcaa cttcttcagt 1140
tgagttatct gaaagtgttg ggcagtgaca ccatgccaaa cactgttaaa ttcattgcat 1200
taaaaacagt ggagtgttct gcaaagcccc attctctgca gctttaagac tggacagtat 1260
tgaaatattc acaggaatct tccaagccgt gaaagcttaa tattaacag cccttttaat 1320
tgcaaaggag aaaaaaatgg agacacttgt gaaaccttgc attctgagtg ctgccacaac 1380
taaatgaagg aattccagaa tttcttcac tacttctgca gtcttaactc tgaattaatg 1440
actgtatata tcaaaacttca gatcttaaaa aacatcagct cgcaagaggc tgaggcagga 1500
gaatgacatg aacctgggag gcggagcttg cagtaagccg agactgagcc actgcatcc 1560
agcctgggca atagagcaag actccatctc aaaaaaaaaa aaaaatcggc tcatctttta 1620
ttgctgttgg ttgagatgaa tctactgatg aagaaaactg tactttgtt acattcagaa 1680
taaggctttc aaaactgtgg gtgtgctgtt ttcgtgagcc ttctacttga ccaccaaaaga 1740

```

cagtattttt gcagctgtat caaatgaacc gagttggagg aaattgtata ggagtatatc 1800
ttaatggcac tacagcaaac tgtgttaat 1829

<210> 14
<211> 2143
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2762870CB1

<400> 14
ggacaacatg gctgcgcccg cactaggggt ggtgtgtgga cgttgccctg agctgggtct 60
cgctcctcttg ctgctgctgc tctcgctgct gtgtggagcg gcagggagcc aggaggccgg 120
gaccggtgcg ggcgcggggg cccttgccgg ttcttgccgc tgcggcacgc ccagcggcc 180
tggcgcccac ggagagcggc aactcgcgca ctcaaagatg gtcccatcc ctgctggagt 240
ccccgtaccc ggagagcggc aactcgcgca ctcaaagatg gtcccatcc ctgctggagt 300
atttacaatg ggcacagatg atcctcagat aaagcaggat ggggaagcac ctgctggagt 360
agttactatt gatgcctttt acatggatgc ctatgaagtc agtaatactg aatttgagaa 420
gtttgtgaac tcaactggct atttgacaga ggctgagaag tttggcgact cctttgtctt 480
tgaaggcatg ttgagtgagc aagtgaagac caatattcaa caggcagttg cagctgctcc 540
ctgggtggtta cctgtgaaag gcgctaactg gagacacca gaagggcctg actctactat 600
tctgcacagg ccggatcatc cagttctcca tgtgtcctgg aatgatgcgg ttgcctactg 660
cacttgggca ggggaagcggc tgcccacgga agctgagtg gaatacagct gtcgaggagg 720
cctgcataat agacttttcc cctggggcaa caaactgcag cccaaaggcc agcattatgc 780
caacatttgg cagggcgagt ttccggtgac caaactgggt gaggatggct tccaaggaac 840
tgcgctgtt gatgccttcc ctcccaatgg ttatggctta tacaacatag tggggaacgc 900
atgggaatgg acttcagact ggtggactgt tcatcattct gttgaagaaa cgcttaacc 960
aaaaggctcc ccttctggga aagaccgagt gaagaaagg ggcctctaca tgtgccatag 1020
gtcttattgt tacaggatc gctgtgctgc tcggagccag aacacacctg atagctctgc 1080
ttcgaatctg ggattccgct gtgcagccga ccgcctgcc actatggact gacaaccaag 1140
gaaagtctt cccagtccaa ggagcagtc tgtctgacct acattgggct tttctcagaa 1200
ctttgaacga tcccatgcaa agaattccca ccctgagggt gggtacatac ctgccaatg 1260
gccaaaggaa ccgccttgtg agaccaaatt gctgacctgg gtcagtgcac gtgctttatg 1320
gtgtggtgca tctttggaga tcatcgccat attttacttt tgagagtctt taaagaggaa 1380
ggggagtgga gggaaacctg agctaggctt caggaggccc gcgtcctacg caggctctgc 1440
cacaggggtt agaccccagg tccgacgctt gaccttctc ggccctcaagt gccctccct 1500
atcaaagtga gggatggaca gcatgacctc tgggtgtctc tccaactcac cagttctaaa 1560
aagggtatca gattctattg tgacttcata gtgagaattt atgatagatt attttttagc 1620
tattttttcc atgtgtgaac cttgagtgat actaatcatg taaagtaaga gttctcttat 1680
gtattatttt cggaagaggg gtgtggtgac tctttatat tcgtactgca ctttgttttt 1740
ccaaggaaat cagtgtcttt tacgttggtt tgatgaatcc cacatggggc cggatgaggt 1800
atgctgcagt tcagccgttg aacacatagg aatgtctgtg gggtgactct actgtgcttt 1860
atcttttaac attaatgtgc tttggttcag aggggcagtc ataagctctg tttccccctc 1920
tccccaaagc cttcagcgaa cgtgaaatgt gcgctaaacg gggaaacctg ttttaattcta 1980
gatataggga aaaaggaacg aggaccttga atgagctata ttcagggtat ccggtatttt 2040
gtaataggga ataggaaacc ttgttggctg tggaaatatc gatgctttga atcatgcact 2100
gtgttgaata aacgtatctg ctaaactcagg cttcacctgc aga 2143

<210> 15
<211> 2310
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5507012CB1

<400> 15
ccgagtgacc gggagccggg ccgcggcctt ccctcgccc cctcgggccc tcccactcct 60
ctgccccggg gccgccaccg cccgggcgtc ggacctggtc ccgtgctcgc ggtgcccgcc 120
ccctctgggc ctagcccgcc cagctcggcg agcggcgcca gtgggagccg cgtcccgccg 180

```

atccgcctcg actcgggtgcc ggccccctggc cctccccctca tgactgcgggc gcctctgctg 240
ccaccgcccc cccggccgccc gctcgcgcga ggatggatgc ggaccgtgcg gcgctaacc 300
ccgtggctca gctcccgaat cgcccgccct cgagccctcc tcgtgagccg cagcagcctc 360
ggtgccagcc cccgcccag ctgggcccag cggtcgcct gtccctcggt gcggcttgct 420
ggtgctgagt gaggcgctgt ccgggtcggc cgggaaccgc ccggccgagg ttccctgcag 480
acctctgcgc gggcggtcgc gcccttcacg cccttttcgt tcacgaatcc gagcccgctc 540
gcctctctcc agcgaaccga ccatgtctgg cggcgccgca gagaagcaga gcagcactcc 600
cggttccctg ttctctcgc cgccggctcc tgccccaag aatggctcca gctccgattc 660
ctccgtgggg gagaaactgg gagccgcggc cgccgacgt gtgaccggca ggaccgagga 720
gtacaggcgc cgccgccaca ctatggacaa ggacagccgt ggggcccggc cgaccactac 780
caccactgag caccgcttct tccgcccggg cgtcatctgc gactccaatg ccactgcact 840
ggagcttccc ggcttctctc ttccctgcc ccagcccagc atccccgcgg ctgtcccgca 900
gagtgtccca ccgggacccc accgggaaga gaccgtgacc gccaccgcca cttcccaggt 960
agcccagcag cctccagccg ctgcccgcgc tggggaacag gccgtcgcgg gccctgcccc 1020
ctcgactgtc cccagcagta ccagcaaaga cggcccagtg tcccagccta gccttggtgg 1080
gagcaaagag gagccgcccgc cggcgagaag tggcagcggc ggccggcagg ccaaggagcc 1140
acaggaggaa cggagccagc agcaggatga tatcgaagag ctggagacca aggccgtggg 1200
aatgtctaac gatggccgct ttctcaagtt tgacatcgaa atcggcagag gctcctttaa 1260
gacggtctac aaaggtctgg aactgaaac caccgtggaa gtcgcctggg gtgaactgca 1320
ggatcgaaaa ttaacaaaagt ctgagaggca gagatttaaa gaagaagctg aaatgttaaa 1380
aggtcttcag catcccaata ttgttagatt ttatgattcc tgggaatcca cagtaaaagg 1440
aaagaagtgc attgttttgg tgactgaact tatgacgtct ggaacactta aaacgtatct 1500
gaaaaggttt aaagtgatga agatcaaagt tctaagaagc tgggtgccgtc agatccttaa 1560
aggtcttcag ttcttctcata ctcgaaactcc acctatcatt caccgcgac tttaatgtga 1620
caacatcttt atcaccggcc ctactggctc agtcaagatt ggagacctcg gtctggcaac 1680
cctgaagcgg gcttcttttg ccaagagtgt gataggtag ccagagttca tggccccgta 1740
gatgtatgag gagaaatatg atgaatccgt tgacgtttat gcttttggga tgtgcatgct 1800
tgagatggct acatctgaat atccttactc ggagtgccaa aatgctgcgc agatctaccg 1860
tcgctgacc agtggggtga agccagccag ttttgacaaa gtagcaattc ctgaagtga 1920
ggaaattatt gaaggatga taccgacaaa caaagatgaa agatattcca tcaaagacct 1980
tttgaacct gccttcttcc aagaggaaac aggagtacgg gtagaattag cagaagaaga 2040
tgatggagaa aaaatagcca taaaattatg gctacgtatt gaagatatta agaaattaaa 2100
gggaaaatac aaagataatg aagctattga gttttctttt gatttagaga gagatgtccc 2160
agaagatgtt gcacaagaaa tggtagagtc tgggtatgtc tgtgaagggt atcacaagac 2220
catggctaaa gctttcaaag acagagtatc attaathtag gggaaacgag agcagcggca 2280
atgtgtacgg gaggagccag gaaaaaaaaa

```

2310

<210> 16

<211> 4699

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6756529CB1

<400> 16

```

gcagcagcgg cggcgccagc cggagcagta ggcacccgag cagcgccagc ggccgagcgg 60
gcggcttctc ggcttgggag ctccggtggc ggcggagggt cgcgcggagc catggttatc 120
atgtcggagt tcagcgcgga ccccgccggc cagggtcagg gccagcagaa gccctccgg 180
gtgggttttt acgacatcga gcggacctg ggcaaaggca acttcgcggt ggtgaagctg 240
gcgcggcatc gattcaccga aacgcaggtt gcaataaaaa taattgataa aacacgatta 300
gattcaagca atttgagaaa aatctatcgt gaggttcagc tgatgaagct tctgaacct 360
ccacacatca taaagcttta ccagggttat gaaacaaagg acatgcttta catcgtcact 420
gaatttgcta aaaatggaga aatgtttgat tatttgactt ccaacgggca cctgagtgag 480
aacgaggcgc ggaagaagtt ctggcaaatc ctgtcggccg tggagtactg tcacgacct 540
cacatcgctc accgggacct caagaccgag aacctcctgc tggatggcaa catggacatc 600
aagctggcag attttgatt tgggaatttc tacaagtcag gagagcctct gtccacgtgg 660
tgtgggagcc ccccgatatg cggcccgga gtctttgagg ggaaggagta tgaaggcccc 720
cagctggaca tctggagcct gggcggtggt ctgtacgtcc tgggtcgcgg ttctctcccc 780
ttcgatgggc ctaacctgcc gacgctgaga cagcgggtgc tggagggccc cttccgcac 840
cccttcttca tgtctcaaga ctgtgagagc ctgatccgcc gcatgctggg ggtggacccc 900
gccaggcgca tcaccatcgc ccagatccgg cagcaccggt ggatgcgggc tgagccctgc 960

```

ttgccgggac	cgccttcccc	cgccttctcc	gcacacagct	acacctccaa	cctggggcgac	1020
tacgatgagc	aggcgctggg	tatcatgcag	accctgggcy	tggaccggca	gaggacgggtg	1080
gagtcactgc	aaaacagcag	ctataaccac	tttgctgccca	tttattacct	cctccttgag	1140
cggctcaagg	agtatcggaa	tgccacgtgc	gcccggcccc	ggcctgccag	gcagccgcgg	1200
cctcggagct	cggacctcag	tggtttggag	gtgcctcagg	aaggctcttc	caccgacctt	1260
ttccgacctg	ccttgctgtg	cccgcagccg	cagaccttgg	tgcagtcctg	cctccaggcc	1320
gagatggact	gtgagctcca	gagctcgctg	cagtggccct	tgttcttccc	ggtggatgcc	1380
agctgcagcg	gagtggtccg	gccccggccc	gtgtcccca	gcagcctgct	ggacacagcc	1440
atcagtgagg	aggccaggca	ggggccgggg	ctagaggagg	agcaggacac	gcaggagtcc	1500
ctgcccagca	gcacggggcg	gaggcacacc	ctggccgagg	tctccaccgc	cctctcccca	1560
ctcaccgcgc	catgtatagt	cgtctcccc	tccaccacgg	caagtctctg	agaggggaacc	1620
agctctgaca	gttgtctgac	cttctctgcy	agcaaaagcc	ccgcggggct	cagtggcacc	1680
ccggccactc	aggggctgct	ggggcgctgc	tccccggcca	ggctggcctc	gcccttccctg	1740
gggtgcagct	ccgccacccc	agtgtgcag	gctcaggggg	gcttgggagg	agctgttctg	1800
ctccctgtca	gcttccagga	gggacggcg	gcgtcggaca	cctcactgac	tcaagggctg	1860
aaggcccttc	ggcagcagct	gaggaagacc	acgcggacca	aagggtttct	gggactgaac	1920
aaaatcaagg	ggctggctcg	ccaggtgtgc	caggtccctg	ccagccgggc	cagcaggggc	1980
ggcctgagcc	ccttccacgc	ccctgcacag	agcccaggcc	tgcacggcgg	cgcaggcggc	2040
agccgggagg	gctggagcct	gctggaggag	gtgctagagc	agcagaggct	gctccagtta	2100
cagcaccacc	cggccgctgc	acccggctgc	tcccaggccc	cccagccggc	ccctgccccg	2160
tttgtgatcg	ccccctgtga	tggccctggg	gctgccccgc	tcccagcac	cctcctcacg	2220
tccgggctcc	cgtgctgccc	gccccactc	ctgcagaccg	gcgcgtcccc	ggtggcctca	2280
gcggcgagc	tcctggacac	acacctgcac	attggcacccg	gccccaccgc	cctccccgct	2340
gtgccccac	cacgcctggc	caggctggcc	ccaggttgtg	agccctggg	gctgctgcag	2400
ggggactgtg	agatggagga	cctgatgccc	tgtcccttag	gcacgtttgt	cctggtgcag	2460
tgagggcagc	cctgcaccc	ggcacggaca	ctgactctta	tagcaataac	ttcagaggag	2520
gtgaagacat	ctggcctcaa	agccaagaac	tttctagaag	cgaataaagc	aatacgttag	2580
gtgttttggc	tttttagttt	atttttgttt	tatttttttc	ttgactgag	tgacctcaac	2640
tttgagtagg	gactggaaac	tttaggaaga	aagataattg	aggggcgtgt	ctgggggcgg	2700
gggcaggagg	ggagcgggg	ggaggggaaca	cgtgcagtgc	cgtggtgtgg	ggaatctcggc	2760
ccctctctct	gggtctgctg	tggttgagat	gattaccctg	gacgtctacg	gaacagagcg	2820
ggcgcatgtt	tgtccgcttg	tgtgtgtgtg	tgtgtgctg	tgtgtgcgcg	tacattgatt	2880
actatccatt	tcttttagtca	acgctctcca	cttccctgatt	tctgctttaa	ggaaaactgt	2940
gaactttctg	cttcatgtat	cagttttaaa	gcagcccagg	caaagatcat	ctacagattc	3000
taggaattct	ctcccctgaa	atcaaaacct	ggaagacttt	ttttcttat	tttagttgag	3060
aagtttcata	aactgctcaa	ggattagttt	tccaggactc	tgcggaggaa	cggcaggaag	3120
aacctcagag	agggcagagg	tgacttcaaa	gtgctgggga	ctccgtccctg	agggtcactt	3180
ggccctgagc	ccctgcgtgc	ccttgcggaa	gcccagaagc	ttcttctctg	tgacctccc	3240
gtttccgctg	ctgctgacgt	ttatgcattt	catgatgggg	tccaacaaga	acactgact	3300
tgggtgaagt	tgtgcaatat	tggaggctga	ctgtagggct	gggcagctgg	gagacaggct	3360
catggctcat	ggctcatggc	tcagggcggt	gctgcccctg	ggccgggacc	cccccccca	3420
ccccccacct	aggctttttg	ggttttgttc	aaggaaaggta	aagtgagagg	tttaggtcag	3480
tgtttttaag	tttttgtttt	ttttttaaag	caaatcctgt	atatgtatct	acatgggaga	3540
caggtagaca	ctacttattt	gttacatttt	gtactacacg	tttgtgttcc	aggtttcagc	3600
ttccctcgct	cctgttggtta	agaagcgctc	ctgtcagcac	aggtgtgcat	tgaggaaggg	3660
gccccagggc	cttcgctccc	tcagcactgg	ggtggaggcg	gcaggaaggg	gcggccctta	3720
cctggcaggt	ctgggcgcac	cttttagcagg	tggactccgt	ggggctccac	cagccagaag	3780
cccttgggaag	gcaacgaagg	caatgctgct	ccctgagctc	agtccccgcc	cccaaaccca	3840
ccccaggctc	cttcagctac	ttcggcttct	ttaaccctgc	agtgttaaag	agaggcattg	3900
agaaagggga	aaggcgggta	tttttaaaag	ccaaagattg	acccagttac	ttgagggtag	3960
ggaggcgggc	ccagtgcagg	aggctgcac	cctggcctgc	tgggtcccac	cgggggctgt	4020
gcctgtgccg	ggccgcaggg	aagctggctg	ccccatttcc	tgtgtgtgct	gctgctgctg	4080
ctctgtggct	gtttcaaaga	ctgggcgaaa	ggctgtccgg	agggcagacc	aggtgccttg	4140
ccgcagagaa	aacaccaaa	tctcctgttc	gtcataaaag	aagttttttg	gatgggagag	4200
aatccagacc	atcttggggc	agccaggccc	ttgccttcat	ttttacagag	gtagcacaat	4260
tgattccaac	acaaaactcc	ttcccccttt	taaaatgatt	tctgttctaa	tgccatagat	4320
caaaggcctc	agaaaccatt	gtgtgtttcc	tctttgaagc	aatgacaagc	actttacttt	4380
cacggtggtt	tttgtttttt	cttattgctg	tggaaacctc	tttgaggagc	gttaaaggcg	4440
tgttttactt	gtttttttta	gagtggttga	tgtgtgtttt	gtagatttct	tgacagtgct	4500
gtaatacaga	cggcaatgca	atagcctatt	taaagacact	acgtgatctg	attgagatgt	4560
acatagtttt	tttttttacc	ataactgaat	tattttatct	cttatgttaa	catgagaaat	4620
gtatgccaaa	tgattagttg	atgtatgttt	tttaatttaa	tatttaaata	aaatatattg	4680
aaggaaaaaa	aaaaaaaaa					4699

<210> 17
 <211> 2649
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 387382CB1

<400> 17
 gcacggaagt ctgcgatgt ttgcgtttga acctcttggc gggcgccggc catggcggct 60
 tcgctcccg gacctgggag ccggcttttc cacacatatg gggctgcgga cggcaggaga 120
 cagcggcggc cgggcccggg agccgcgcag tggttcccg cgcaggaccg gaggcgtttc 180
 ttcaacagca gcggcagcag cgacgccagc atcggcgacc cctcgcagtc cgacgatcct 240
 gacgatcccg acgaccccga cttccccggc agcccgggtga ggcggcggcg aaggtgtccc 300
 ggcggccgag tgcccaagga ccggccccagc ctgaccgtga ccccaaagcg ctggaagctg 360
 cgagctcgcc caagcctaac cgtgacccca agacgcctgg ggctgcgagc tcggcccccg 420
 cagaagtga gcacaccctg tggcccgtc cgacttccgc ccttccccag ccgcgactcc 480
 ggccgcctca gcccggacct cagcgtgtgc ggccagccca gggacggcga cgagctgggc 540
 atcagtgcct ccctgttcag ctctctggcc tcgccctgcc ccgggtcccc aacgccagg 600
 gacagtgtca tctcgatcgg cacctccgcc tgtctgggtg cagcctcagc cgtcccagc 660
 ggcctccacc tcccagaagt ctccctggac cgagcatctc tcccctgctc ccaggaggaa 720
 gcgacaggag gagccaagga caccaggatg gtccaccaa cccgcgccag cctcagggtca 780
 gttctctttg gccttatgaa ctcagggaacc cctgaggatt ctgagtttcg ggcagatggg 840
 aagaatatga gagagtctc ctgtaaaagg aaactgggtg tgggaaatgg accagaggt 900
 ccagggtctg caagcacagg caagaggagg gccacaggcc aggactcttg tcaagagaga 960
 gggcttcaag aggcctccg gagagagcat caggaggcca gtgttcccaa gggccgcatt 1020
 gtgccaaagg gaatagacag gctggagaga actagatcaa gccggaagag caaacatcag 1080
 gaggcaacgg aaacctctct cctccattcc caccgcttta aaaagggcga aaagctggga 1140
 aaagattcgt tccccacca ggacctgact cctttacaga atgcctgctt ttggaccaa 1200
 accagggtct ccttcagttt ccacaagaag aaaattgtga ctgatgtgtc agagggtctgc 1260
 agcatctata ccactgccac ttctctctct ggatccctcc tatcagaatg ttcaaaccgg 1320
 cctgtcatga acagaacaag tgggtgctcg tcccttggc actcctctc tatgtatttg 1380
 ctaagccct taaacactct aagtatttca aacaaaaagg catctgatgc tgaaaaggtt 1440
 tatggggaat gcagtcagaa gggctctgtc ccctttagcc attgccttc cacagaaaaa 1500
 ctgcaacgct gtgagaagat tggggaaggg gtgtttggcg aagtgtttca aacaattgct 1560
 gatcacacac ccgtagccat aaaaatcatt gctattgaag gaccagattt agtcaatgga 1620
 tcccatcaga aaacctttga ggaaatcctg ccagagatca tcatctccaa agagttagc 1680
 ctcttatccg gtgaagtgtg caaccgcaca gaaggcttta tcgggctgaa ctcagtgcac 1740
 tgtgtccagg gatcttacc tcccttgctc ctcaaagcct gggatcacta taattcaacc 1800
 aaaggctctg caaatgaccg gcctgatttt tttaaagacg accagctctt cattgtgctg 1860
 gaatttgagt ttggagggat tgacttagag caaatgcaa ccaagttgtc ttccttggct 1920
 actgcaaaga gcattctaca ccagctcaca gctcctctcg cagtggcaga ggcactactg 1980
 cgctttgagc accgagactt aactggggg aacgtgctct taaagaaaac cagcctcaaa 2040
 aaactccact acaccctcaa tgggaagagc agcactatcc ccagctgtgg gttgcaagt 2100
 agcatcattg actacacct gtcgcgcttg gaacgggatg ggattgtggt tttctgtgac 2160
 gtttccatgg atgaggacct gtttaccggt gacgggtgact accagtttga catctacagg 2220
 ctcatgaaga aggagaataa caaccgctgg ggtgaatatc acccttatag taatgtgctc 2280
 tggttacatt acctgacaga caagatgctg aaacaaatga cttcaagac taaatgtaac 2340
 actcctgcc tgaagcaaat taagagaaaa atccaggagt tccacaggac aatgctgaac 2400
 ttcagctctg ccactgactt gctctgccag cacagtctgt ttaagtaagc taaatgtatc 2460
 ttactggccc gaaatgagag gagactggtc ttgaagctc tgggtgctgt tcaacctcca 2520
 tccccacagg aggggtgggac tcccattctc acagggttcc agtcagcttt ttcaacaaga 2580
 attttgtttc aaattggaac ctgaatatgt gttgaaatgt ttaaatttgc tgggtacaaat 2640
 gttctgaag 2649

<210> 18
 <211> 2526
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature

<223> Incyte ID No: 5850786CB1

<400> 18

```

tgcgcccggg gagaccggga acatggcgct gggagcgctg tagcagctga gaaggggctg 60
aggcaccgcc gcttcgctga cagccggcca ccagaaatac actgtggtga aatgcttcca 120
cctcttgcta aaatgaacac tgaggaaaaa tgaagaagac tgacaagcac cagcgaaaag 180
ttgcagaata gaaatagcca cactcctctg gagtctttaa ttcattccaca gccatcatat 240
aaagggttttg gcatcatgtt tgggaagaaa aagaaaaaga ttgaaatatc tggcccgtcc 300
aactttgaac acagggttca tactgggttt gatccacaag agcagaagtt taccggcctt 360
ccccagcagt ggcacagcct gttagcagat acggccaaca ggccaaagcc tatggtggac 420
ccttcagtga tcacacccat ccagctggct cctatgaaga caatcgtagg aggaaacaaa 480
ccctgcaagg aaacctccat caacggcctg ctagaggatt ttgacaacat ctccgtgact 540
cgctccaact ccctaaggaa agaaagccca cccaccccag atcagggagc ctccagccac 600
ggtccaggcc acgcggaaga aaatggcttc atcaccttct cccagtattc cagcgaatcc 660
gatactactg ctgactacac gaccgaaaag tacagggaga agagtctcta tggagatgat 720
ctggatccgt attatagagg cagccacgca gccaaagcaa atgggcacgt aatgaaaatg 780
aagcacgggg aggcctacta ttctgagggt aagcctttga aatccgattt tgccagattt 840
tctgccgatt atcactcaca tttggactca ctgagcaaac caagtgaata cagtgcctc 900
aagtgggagt atcagagagc ctccagtagc tccccctctg attattcatt ccaattcaca 960
ccttctagaa ctgcagggac cagcgggtgc tccaaggaga gcctggcgta cagtgaaggt 1020
gaatggggac ccagcctgga tgactatgac aggaggccaa agtcttcgta cctgaatcag 1080
acaagccctc agcccacat gcggcagagg tccaggctag gctcgggact ccaggaaccg 1140
atgatgccat ttggagcaag tgcattttaa acccatcccc aaggacactc ctacaactcc 1200
tacacctacc ctgccttgtc cgagcccaca atgtgcattc caaagggtga ttacgatcga 1260
gcacagatgg tctcagccc tccactgtca ggggtctgaca cctaccccag gggccctgcc 1320
aaactacctc aaagtcaaag caaatcgggc tattectcaa gcagtcacca gtaccctct 1380
gggtaccaca aagccacctt gtaccatcac cctccctgc agagcagttc gcagtacatc 1440
tccacggctt cctacctgag ctccctcagc ctctcatcca gcacctacc gccgccagc 1500
tggggctcct cctccgacca gcagccctcc aggggtgtccc atgaacagtt tcgggcggcc 1560
ctgcagctgg tggtcagccc aggagacccc aggggaatac tggccaactt tatcaaatc 1620
ggggaaggct caaccggcat cgtatgcac gccaccgaga aacacacagg gaaacaagtt 1680
gcagtgaaga aaatggacct ccggaagcaa cagagacgag aactgctttt caatgaggtc 1740
gtgatcatgc gggattacca ccatgacaat gtggttgaca tgtacagcag ctacctgtc 1800
ggcgtagagc tctgggtggt catggagttt ctagaagggt gtgccttgac agacattgtg 1860
actcacacca gaatgaatga agaacagata gctactgtct gcctgtcagt tctgagagct 1920
ctctcctacc ttcataacca aggagtgatt cacagggaca taaaagtgat ctccatcctc 1980
ctgacaagcg atggccgggt ttcttcagtg ctccggggat tccatagact gatgttggtg 2040
aggagccct ctccagagagc aacagcccag gaactcctcg gacatccatt cttaaaacta 2100
gcaggccac cgtcttgcat cgtccccctc atgagacaat acaggcatca ctgagcagag 2160
gattcgtgta ggtggcaaag ctatagagg acatgagaat aattcaggag aacaaaagga 2220
aacacagaac atgcaaaaagg cctgtgcatt ctagaccagc caattggtgg gacagcgtga 2280
tgaccggcag ggttcaacag accagggcat cttcttgtgt cttaaacagg catctctcca 2340
ctgacagcgg gtgtggtcac ttggagcacg gctttaataa gtcattatta tatttttcag 2400
cccttcatcc agcaaatcag aaggactcag tacaactcc gttatgatat atcctagcca 2460
catgcagggt aacatgtagg attttctata ttgaaagaat acttttctg caaaaaaaaa 2520
aaaagg 2526

```

<210> 19

<211> 2178

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7182343CB1

<400> 19

```

gtggcgagc cccctgcctg ggtgtccagg ctgtcccggc tggggctggg ggagctagag 60
gccacggggg agttggggga gtcctcagg gccccctca cctgccctcc ctgtgcacct 120
ccgtctctct gcagatgaca ttagcccagg gaaggagagc ctggggcccg acagctcctc 180
tgggggctca gaggaccccg ccagccagca gtgggcacga ccgcgcttca cacagccctc 240
caagatgagg cgccgggtga tcgcacggcc cgtgggtagc tccgtgcggc tcaagtgcgt 300
ggccagcggg caccctcggc ccgacatcac gtggatgaag gacgaccagg ccttgacgcg 360

```



```

cccagaggcc gctgagccca ggaagaagaa gtggacactg agcctgaaga acctgcggcc 420
ggaggacagc ggcaaataca cctgccgcgt gtgcaaccgc gcggggcgcca tcaacgcccac 480
ctacaagggt gatgtgatcc agcggaccgc ttccaagccc gtgctcacag gcacgcaccc 540
cgtgaacacg acggtggact tcggggggac cacgtccttc cagtgcagg tgccgcagca 600
cgtgaagccg gtgatccagt ggctgaagcg cgtggagtac ggcgccgagg gccgccacaa 660
ctccaccatc gatgtgggcg gccagaagtt tgtgggtgctg ccacgggtg acgtgtgggtc 720
gcggcccgac ggctcctacc tcaataagct gctcatcacc cgtgcccgcg aggacgatgc 780
gggcatgtac atctgccttg gcgccaacac catgggctac agcttcgcga gcgccttctc 840
caccgtgctg ccagacccaa aaccgccagg gccacctgtg gcctcctcgt cctcgccac 900
tagcctgccc tggcccgtgg tcatcgcat ccagccggc gctgtcttca tcctggggc 960
cctgctcctg tggctttgcc agggccagaa gaagccgtgc acccccgcg cgtcccctcc 1020
cctgcctggg caccgccgcg cggggacggc ccgcgaccgc agcggagaca aggaccttc 1080
ctcgctggcc gccctcagcg ctggccctgg tgtggggctg tgtgaggagc atgggtctcc 1140
ggcagccccc cagcacttac tgggcccagg ccagttgct ggcctaagt tgtaccccaa 1200
actctacaca gacatccaca cacacacaca cacacactct cacacacact cacacgtgga 1260
gggcaaggct caccagcaca tccactatca gtgctagacg gcaccgtatc tgcagtggg 1320
acgggggggg cggccagaca ggcagactgg gaggatggag gacggagctg cagacgaagg 1380
caggggaccc atggcgagga ggaatggcca gcacccagg cagtctgtgt gtgaggcata 1440
gcccctggac acacacacac agacacacac actacctgga tgcattgtatg cacacacatg 1500
cgcgcacacg tgctccctga aggcacacgt acgcacacac gcacatgcac agatatgccg 1560
cctgggcaca cagataagct gcccaaatgc acgcacacgc acagagacat gccagaacat 1620
acaaggacat gctgcctgaa catacacacg cacacccatg cgcagatgtg ctgcctggac 1680
acacacacac acacggatat gctgtctgga cgcacacacg tgcagatatg gtatccggac 1740
acacacgtgc acagatatgc tgcttggaaca cacagataat gctgccttga cacacacatg 1800
cacggatatt gcctggacac acacacacac acgcgtgcac agatatgctg tctggacagg 1860
cacacacatg cagatatgct gcctggacac acacttccag acacacgtgc acaggcgag 1920
atatgctgcc tggacacacg cagatatgct gtctagtcac acacacacgc agacatgctg 1980
tccggacaca cacacgcacg cacagatatg ctgtccggac acacacacgc acgcagatat 2040
gctgcctgga cacacacaca gataatgctg cctcaacact cacacacgtg cagatatgct 2100
ctggacacac acatgtgcac agatatgctg tctggacatg cacacacgtg cagatatgct 2160
gtccggatag acacgcac

```

2178

<210> 20

<211> 2777

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7264345CB1

<400> 20

```

ctcagcagag ctaccagctg cctgtttggc ttctgtggtc ggatcgtcct cctggccccg 60
ceaaacaggc ggggggagcg gcccgcactg tggggccatg gcagtagtct cctcgttcgc 120
cgccgcccgt agcctagctg agtcgccggc ttctgcgcta ggggctccca ccgcctccgc 180
aggctaagga gccgctgcca ccaacgagct gtgagggtta ctatgctccc tctttgccgc 240
cgtctcctcc tcttgcccgc gcaggcacc cctctggctgc tcagtcctgc ctcagtgtca 300
aaccagaaga gaagtaaaat tcaacaaaaa tttatgtgtg gatttccttc ttaaaagaag 360
aaaaaagtga ttatttagac tatggatcgg agcaaacgga attcaattgc aggtttcct 420
ccacgtgtgg agcgtcttga agagtttgaa ggaggtgggtg gaggagaagg aaatgtgagc 480
caggtgggaa gattttggcc atcttcgtat cgagctctta taagtgcctt ttccagactg 540
acgcgttttg atgatttcac ctgtgaaaaa atagggtctg gcttcttttc tgaagtgttc 600
aaggtacgac accgagcttc tggtcagggt atggctctta agatgaacac attgagcagt 660
aaccgggcaa acatgctgaa agaagtacag ctcattgaata gactctccca tcccaacatc 720
cttaggttca tgggtgtatg tgttcatcaa ggacaattgc atgcacttac agagtatatc 780
aactccggga acctggaaca gttgctagac agtaacctgc atttgccttg gactgtgagg 840
gtaaaactgg cctatgacat agcagtgggc ctcagctacc ttcacttcaa aggcattttt 900
catcgggacc tcacatctaa gaactgcctg ataaagaggg atgagaatgg ttactctgca 960
gtggtagctg actttggcct ggctgagaag atccccgatg tcagcatggg gagtgagaag 1020
ctggccgtgg tgggttcccc attctggatg gcacctgagg ttctccgaga tgagccctat 1080
aatgaaaagg cagatgtgtt ctcttatggt atcatcctct gcgagatcat cggccgcac 1140
caggccgatc cggactatct tccccgcaca gagaatttcg ggctggacta tgatgctttc 1200
cagcacatgg tgggagactg tccccagat tttctgcaac ttactttcaa ctgctgtaac 1260

```



```

atggatccca aactgcgccc atcttttgtg gagattggga agaccctgga ggaaattctg 1320
agccgcctac aggaagaaga gcaggagagg gataggaagc tgcagcccac agccagggga 1380
ctcttgagaa aagcacctgg ggtgaagcga ctaagctcac tggatgacaa gatccccac 1440
aagtacccat gcccaagacg taccatctgg ctgtctcgaa gccagtcaga tatcttttcc 1500
cgtaagcccc cacgtacagt gagtgtcttg gaccatact accggccacg agatggtgct 1560
gcccgcaccc ccaaagtcaa cccttttagt gctcgccagg acctcatggg gggcaagatc 1620
aagttttttg acctgcccag caagtctgtc atctctctgg tatttgacct ggatgcacca 1680
gggcccggaa ctatgcccct ggctgactgg caggagcccc tggccccacc tattcgccgg 1740
tggcgttcct tgccctggttc gcctgagttc ttgcatcaag aggcttgtcc atttgtgggc 1800
cggaagaat cgctatctga tgggccccca ccacgcctaa gtagtctcaa gtacagagtt 1860
aaagatagtc caccattccg ggcatctgcc ctaccagctg ctcaagccca tgaggctatg 1920
gactgctcca ttctccagga agaaaatggg tttgggtcca ggccccaggg gaccagtcca 1980
tgccctgcgg gtgcttctga ggagatggag gtagaagaaa ggccagcagg ctcaactcca 2040
gccaccttct ccacctcagg cataggcctg caaaccaggg gaaagcagga tgggtgaggg 2100
ggtttagtc ctgcctcacc ttggggatgg accttcagct gaaaccatat ggccccctag 2160
gtgcacagcc ttgattcttc cctggagcct acagagcagg caggctaggc caagccaggc 2220
tcaacttctg ggctcccagt gccattggc tgtgtatgac gggaggcagc agtgagaggc 2280
cttcctagtt agggccaaca gctgatacca agcctctgaa atccagcaag gaggtctgcc 2340
tcccaccaga ccctctccag tgtacttccc cagataggac cagaggatgt ctagttctag 2400
gctgagctgg caggcagcta ttaccccggt tctttcccca cccagggtct gtctcttgcc 2460
tttcttggg gcatataagc tactgagtg aacatggagc tgatcaagag gccgtaatgg 2520
tcatggctgt tcccagacc tgaatatgg ggtgcttctt gccagtattc taagacattt 2580
gagtaattgc tgtttgcact tactgcatgg tcagaccag tcactacatt tctatgcaag 2640
gggacagcaa ggcagcgtgg tggtcatggc tcttagctaa cctattcaaa gaccttttcc 2700
tgttgattaa tctattttca tatttataaa ggagtcttaa tgttctgccc cataagactt 2760
tcaacctgtg ggttggg 2777

```

<210> 21

<211> 972

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472328CB1

<400> 21

```

atgcgagcca cccctttggc tgcttctgcg ggttccctgt ccaggaagaa gcggttgagg 60
ttggatgaca acttagatac cgagcgtccc gtccagaaac gagctcgaag tgggccccag 120
cccagactgc cccctgcct gttgcccctg agccaccta ctgctccaga tcgtgcaact 180
gctgtggcca ctgcctcccg tcttggggcc tatgtcctcc tggagccga ggagggcg 240
cgggcctacc aggcctgca ctgccctaca ggcactgagt atacctgcaa ggtgtacccc 300
gtccaggaag ccctggccgt gctggaaccc tatgcgcggc tgcccccgga caagcatgtg 360
gcttggccca ctgagggcct ggctgggtacc caacttctct acgccttttt cacttggaac 420
catggggaca tgcacaggct gatagggcac acgcctctgt cgcactgtga ccagacacgg 480
aagaagctgg tgctggagaa cctggaggac tcttgctgtc tgactgggcc agatgattcc 540
ctgtgggaca agcacgcgtg cccagcctac gtgggacctg agatactcag ctcacggggc 600
tcatactcg gcaaggcagc caatgtctgg agcctgggcg tggcgctctt caccatgctg 660
gccggccact accccttcca ggactcggag cctgtcctgc tcttcggcaa gatccgccg 720
ggggcctacg ccttgccctg aggcctctcg gcccctgccc gctgtctggg tcgctgcctc 780
cttcgtcggg agccagctga acggctcaca gccacaggca tcttctctga cccctggctg 840
cgacaggacc cgatgccctt agcccccaacc cgatcccatc tctgggaggc tgcccagggtg 900
gtccctgatg gactggggct ggacgaagcc agggaagagg agggagacag agaagtgggt 960
ctgtatggct ag 972

```

<210> 22

<211> 2538

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1471412CB1

<400> 22

```

ggggccgtgg ctccgagctg cctagaaagc ggctccaggg agccagggca ccgtgagcct 60
ggtgggttggc agctggagcc acgtcggagg gggaagtgtc gcagcattct ctgcaggcat 120
cacagacctg aggcagtggc ctccggaggg cactggacag aaacagccat ccaagtggct 180
gagtggaggg accctgtca agtgcagctg cagtggccgg ggtttccctc aggtagggat 240
cggggcgccct tgtcgccgcc agccacgtgt ggctccggt acagtacagc agtgcaggg 300
tgcgggcacc aggaaagggg gcgcagggga actcccgcg gcctcgctt tgcaaacttc 360
tcgcctgggc aggaggcggc cgtgggaaag aaggtggaag agcgagcttt ttggaactgt 420
gcacgggaca gattggacgc acaccctcg ggaggcgcga aggcattgaa aatttgaagc 480
atattatcac ccttggccag gtcattccaca aacggtgtga agagatgaaa tactgcaaga 540
aacagtgcgc gcgcctgggc caccgcgtcc tcggcctgat caagcctctg gagatgctcc 600
aggaccaagg aaagaggagc gtgcctctcg agaagttaac cacagccatg aaccgcttca 660
aggctgccct ggaggaggc aatggggaga tagaaaagtt cagcaataga tccaatatct 720
gcaggtttct aacagcaagc caggacaaaa tactcttcaa ggacgtgaac aggaagctga 780
gtgatgtctg gaaggagctc tcgctgttac ttcaggttga gcaacgcag cctgtttcac 840
ccataagcca aggagcgtcc tgggcacagg aagatcagca ggatgcagac gaagacaggc 900
gagctttcca gatgctaaga agagataatg aaaaaataga agcttactg agacgattag 960
aatcaacat gaaagaaatc aaggaaactt tgaggcagta tttaccacca aaatgcatgc 1020
aggagatccc gcaagagcaa atcaaggaga tcaagaagga gcagctttca ggatccccgt 1080
ggattctgct aagggaaaat gaagtacgca cactttataa aggagaatac cacagagctc 1140
cagtggccat aaaagtattc aaaaaactcc aggtggcag cattgcaata gtgaggcaga 1200
ctttcaataa ggagatcaaa accatgaaga aattcgaatc tccaacatc ctgcgtatat 1260
ttgggatttg cattgatgaa acagtgactc cgcctcaatt ctccattgtc atggagtact 1320
gtgaactcgg gacctgagg gagctgttgg atagggaaaa agacctcaca ctggcaagc 1380
gcatggctct agtcctgggg gcagcccag gcctataacc gctacaccat tcagaagcac 1440
ctgaactcca cggaaaaatc agaagctcaa acttcctggt aactcaaggc taccaagtga 1500
agcttgcagg atttgagttg aggaaaacac agacttccat gagtttggga actacgagag 1560
aaaagacaga cagagtcaaa tctacagcat atctctcacc tcaggaactg gaagatgtat 1620
tttatcaata tgatgtaaag tctgaaatat acagctttgg aatcgctctc tgggaaatcg 1680
ccactggaga tatcccgttt caaggctgta attctgagaa gatccgcaag ctggtggctg 1740
tgaagcggca gcaggagcca ctgggtgaag actgcccttc agagctgcgg gagatcattg 1800
atgagtgccg ggcccatgat cctctgtgct ggccctctgt ggatgaaatc ttaaagaaac 1860
tctccacctt ttctaagtag tgtatcaaaa tctaaaccaa ggagtctctg gacaagaagc 1920
tgggagaggc acaaactgga catctctctc tctcatatcc ttccgcatg gggtatctat 1980
gggagcaagg agtgggcacg cttctctgtt acaaatagaa aacgattcca gtcatacagg 2040
acacatccca ctccaaatga tatttccaaa aacatacctc tgacagtaac tttgatagat 2100
ggtttgtcaa atgtatcttt ctgggtatcc acaoctcttg gcaatgaaat ttgcagctcc 2160
tcccttccat aaatgaagtc tctttcccca ccatttgaat ctgggctggc actgtgactt 2220
gatttgatca atagaatgtg gaagaagtga ctgtatgcca gttccaagcc taggtttcaa 2280
gaggccttat aaatgtctgt tggaaacctt ccagccatg aacatgttga gtgagcatgc 2340
tggagaatga gagaccacat gaagcagaaa catgctttcc tagctgaagt catactagc 2400
caaccaacat ggcagctaac acatgaatga ggccaatcaa gaccagaaga accactcaag 2460
cagatcccag cccaaattgc ccattcacac aatcaggagc taaataaatt actgttgtct 2520
taaaaaaaaa aaaaaaaaaa
2538

```

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60991 A3

(51) International Patent Classification⁷: **C12N 9/12**,
15/54, 5/10, A01K 67/027, C07K 16/40, C12Q 1/68,
C12N 15/11, A61K 38/45, G01N 33/53

(21) International Application Number: PCT/US01/05240

(22) International Filing Date: 16 February 2001 (16.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/183,682	17 February 2000 (17.02.2000)	US
60/186,559	2 March 2000 (02.03.2000)	US
60/188,606	9 March 2000 (09.03.2000)	US
60/189,998	17 March 2000 (17.03.2000)	US
60/193,851	30 March 2000 (30.03.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/183,682 (CIP)
Filed on	17 February 2000 (17.02.2000)
US	60/186,559 (CIP)
Filed on	2 March 2000 (02.03.2000)
US	60/188,606 (CIP)
Filed on	9 March 2000 (09.03.2000)
US	60/189,998 (CIP)
Filed on	17 March 2000 (17.03.2000)
US	60/193,851 (CIP)
Filed on	30 March 2000 (30.03.2000)

(71) Applicant (for all designated States except US): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TANG, Y., Tom** [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **BUFORD, Neil** [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue #1, Menlo Park, CA 94025 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94024 (US). **KHAN, Farrah, A.** [IN/US]; 333 Escuela Avenue #221, Mountain View, CA 94040 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **HAFALIA, April** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **SHIH, Leo, L.** [US/US]; Apartment B, 1081 Tanland Drive, Palo Alto,

CA 94303 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **BURRILL, John, D.** [US/US]; 650 Emerald Hill Road, Redwood City, CA 94061 (US). **MARCUS, Gregory, A.** [US/US]; 1713 Connecticut Drive, Redwood City, CA 94061 (US). **ZINGLER, Kurt, A.** [US/US]; 723 Ashbury Street #C, San Francisco, CA 94117 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **BANDMAN, Olga** [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). **POLICKY, Jennifer, L.** [US/US]; 4864 National Avenue, San Jose, CA 95124 (US). **GRIFFIN, Jennifer, A.** [US/US]; 181 Irene Court #11, Belmont, CA 94002 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). **NGUYEN, Danniell, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **LAL, Preeti** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB).

(74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
21 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.



WO 01/60991 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/05240

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/12 C12N15/54 C12N5/10 A01K67/027 C07K16/40
 C12Q1/68 C12N15/11 A61K38/45 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, BIOSIS, SEQUENCE SEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 47686 A (CADUS PHARMACEUTICAL CORP ;JOHNSON GARY L (US)) 23 September 1999 (1999-09-23) the whole document	1-28
X	WO 98 01756 A (UNIV WASHINGTON) 15 January 1998 (1998-01-15) the whole document	1-28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 September 2001

Date of mailing of the international search report

03 01 02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ROSOK OYSTEIN ET AL: "Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis." GENOMICS, vol. 61, no. 1, 1 October 1999 (1999-10-01), pages 44-54, XP002178442 ISSN: 0888-7543 cited in the application the whole document</p>	1-28
X	<p>--- TAKAHASHI M ET AL: "RET TRANSFORMING GENE ENCODES A FUSION PROTEIN HOMOLOGOUS TO TYROSINE KINASES" MOLECULAR AND CELLULAR BIOLOGY, vol. 7, no. 4, 1987, pages 1378-1385, XP001027825 ISSN: 0270-7306 cited in the application the whole document</p>	1-28
X	<p>--- WO 99 04265 A (SAHIN UGUR ;TURECI OZLEM (DE); PFREUNDSCHUH MICHAEL (DE); GOUT IVA) 28 January 1999 (1999-01-28) SEQ.ID.N.602 and 608 abstract</p>	1-5, 11-15
A	<p>--- HANKS S K: "HOMOLOGY PROBING: IDENTIFICATION OF CDNA CLONES ENCODING MEMBERS OF THE PROTEIN-SERINE KINASE FAMILY" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 84, January 1987 (1987-01), pages 388-392, XP000941941 ISSN: 0027-8424 the whole document</p>	1-5, 11-15
A	<p>--- DATABASE EMBL [Online] SWALL:075460, 1 November 1998 (1998-11-01) Database accession no. 075460 XP002178443 PROTEIN KINASE/ENDORIBONULCEASE. IRE1. Homo sapiens. Tirasophon W. et al., Genes Dev. 12:1812-1824(1998). abstract</p>	1-5, 11-15
	<p>--- -/--</p>	

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/US 01/05240

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL [Online] SWALL:Q9P2I7, 1 October 2000 (2000-10-01) Database accession no. Q9P2I7 XP002178444 KIAA1360 PROTEIN (FRAGMENT). Nagase T., et al., DNA Res. 7:65-73(2000). abstract</p> <p>---</p>	1-5, 11-15
P,X	<p>DATABASE EMBL [Online] 29 September 2000 (2000-09-29) Database accession no. AK024274 XP002178445 Homo sapiens cDNA FLJ14212 fis, clone NT2RP3003500, weakly similar to SCY1 PROTEIN. "NEDO human cDNA sequencing project" abstract</p> <p>---</p>	1-5, 11-15
P,X	<p>WO 00 73469 A (PLOWMAN GREGORY D ;SUGEN INC (US); WHYTE DAVID (US); MARTINEZ RICA) 7 December 2000 (2000-12-07) SEQ ID NO: 85,87, 206 and 203. the whole document</p> <p>---</p>	1-28
P,X	<p>EP 1 074 617 A (HELIX RES INST) 7 February 2001 (2001-02-07) SEQ ID NO:3526,10616,11982,17238 and 18710 abstract page 3 & DATABASE EMBL [Online] 26 June 2001 (2001-06-26) Database accession nos.: AAH06691; AAH13724; AAH14480; AAH17672;AAH18549. abstract</p> <p>---</p>	1-5, 11-15
T	<p>DATABASE EMBL [Online] SWALL:BAB55194, 14 June 2001 (2001-06-14) Database accession no. BAB55194 XP002178446 CDNA FLJ14645 FIS, CLONE NT2RP2001839, WEAKLY SIMILAR TO SCY1 PROTEIN. "NEDO human cDNA sequencing project." abstract</p> <p>-----</p>	1-5, 11-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/05240

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 18,21,24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-28, all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.1; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.12; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.1; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.1.

2. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.2; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.13; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.2; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.2.

3. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.3; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.14; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.3; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.3.

4. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.4; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.15; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.4; methods for treating the disease associated with PKIN expression; methods for screening of

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.4.

5. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.5; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.16; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.5; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.5.

6. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.6; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.17; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.6; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.6.

7. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.7; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.18; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.7; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.7.

8. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.8; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.19; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.8; methods for treating the disease

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.8.

9. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.9; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.20; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.9; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.9.

10. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.10; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.21; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.20; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.20.

11. Claims: 1-28, all partially

An isolated polypeptide comprising an amino acid sequence consisting of SEQ.ID.N.11; a method to produce such polypeptide; non-human transgenic organisms; an isolated polynucleotide comprising a polynucleotide sequence consisting of SEQ.ID.N.22; a method for detecting such polynucleotide, probes thereof; a composition containing the polypeptide of SEQ.ID.N.11; methods for treating the disease associated with PKIN expression; methods for screening of agonists, antagonists and modulators of the polypeptide of SEQ.ID.N.11.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/05240

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9947686	A	23-09-1999	AU 3354499 A	11-10-1999
			WO 9947686 A2	23-09-1999
			US 6312934 B1	06-11-2001

WO 9801756	A	15-01-1998	US 5863729 A	26-01-1999
			AU 3651597 A	02-02-1998
			WO 9801756 A1	15-01-1998

WO 9904265	A	28-01-1999	US 6218521 B1	17-04-2001
			US 6043084 A	28-03-2000
			AU 8571598 A	10-02-1999
			EP 0996857 A2	03-05-2000
			JP 2001516009 T	25-09-2001
			WO 9904265 A2	28-01-1999

WO 0073469	A	07-12-2000	AU 5173400 A	18-12-2000
			WO 0073469 A2	07-12-2000

EP 1074617	A	07-02-2001	AU 6180800 A	19-02-2001
			AU 6180900 A	19-02-2001
			AU 6181000 A	19-02-2001
			AU 6181100 A	19-02-2001
			AU 6181200 A	19-02-2001
			AU 6181300 A	19-02-2001
			AU 6181400 A	19-02-2001
			AU 6181500 A	19-02-2001
			AU 6181600 A	19-02-2001
			AU 6315800 A	19-02-2001
			EP 1074617 A2	07-02-2001
			WO 0109315 A1	08-02-2001
			WO 0109345 A1	08-02-2001
			WO 0109316 A1	08-02-2001
			WO 0109349 A1	08-02-2001
			WO 0109317 A1	08-02-2001
			WO 0109318 A1	08-02-2001
			WO 0109319 A1	08-02-2001
			WO 0109346 A1	08-02-2001
			WO 0109320 A1	08-02-2001
			WO 0109321 A1	08-02-2001
			WO 0109322 A1	08-02-2001
			WO 0109323 A1	08-02-2001

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPT